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ABSTRACT	
	
The	actively	myelinating	oligodendrocyte	is	vital	for	the	normal	development	
and	proper	function	of	the	central	nervous	system	(CNS).	Despite	significant	
progress	in	recent	years,	many	fundamental	questions	remain	regarding	the	cellular	
and	molecular	properties	of	oligodendrocytes.	In	this	dissertation,	we	first	sought	to	
identify	and	characterize	putative	negative	regulators	of	CNS	myelination.	We	
identified	Shp2,	a	protein	tyrosine	phosphatase,	as	a	potential	negative	regulator	of	
CNS	myelination	using	a	candidate	based	approach	and	expression	profiling	of	
mRNA	and	protein	during	development	in	wild	type	and	hypermyelinating	mutant	
mice.	We	then	characterized	the	functional	role	of	oligodendrocyte	Shp2	using	
inducible	and	conditional	transgenic	mice.	We	demonstrated	that	Shp2	regulated	
oligodendrocyte	differentiation	during	postnatal	development	and	acted	as	a	
transient	brake	during	early	myelin	formation.	Shp2	also	regulated	the	timely	
remyelination	following	experimental	demyelination.	The	second	objective	of	this	
project	was	to	examine	the	responses	of	the	actively	myelinating	oligodendrocyte,	
which	are	enriched	in	the	brain	during	late	pediatric	development,	to	ischemic	
injury.	Using	an	established	mouse	model	of	experimentally	induced	reversible	
iv	
cerebral	ischemia,	we	demonstrated	that	actively	myelinating	oligodendrocytes	in	
the	late	pediatric	brain	were	uniquely	resistant	to	ischemia-induced	damage	
compared	to	adult	mice	with	the	same	injury.	We	showed	that	this	difference	could	
be	due	to	pediatric	oligodendrocytes	having	a	more	robust	anti-oxidant	capacity.	We	
also	exmined	other	glial	responses	unique	to	pediatric	stroke	and	found	that	
astrogliosis,	fibrosis,	NG2-cell	responses	and	vascular	integrity	were	all	different	in	
pediatric	compared	to	adult	animals.	Combined,	these	differences	in	stroke	
response	led	to	greater	long-term	tissue	preservation	in	pediatric	mice.	Taken	
together,	this	thesis	provides	significant	improvements	to	our	understanding	of	the	
actively	myelinating	oligodendrocyte,	both	during	development	and	following	
injury.	These	results	could	influence	our	understanding	of	prominent	neurological	
diseases,	such	as	multiple	sclerosis	and	stroke.	
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CHAPTER	I	
INTRODUCTION	AND	BACKGROUND1	
	 	
Oligodendrocytes:	function	and	development	
	
Oligodendrocytes	are	the	myelin-producing	cells	of	the	central	nervous	
system	(CNS).	Myelin	is	the	specialized,	lipid-rich,	multilayered	membrane	that	
forms	an	insulating	sheath	around	axons.	Traditionally	considered	an	evolutionary	
adaptation	resulting	in	rapid	and	efficient	transduction	of	action	potentials	via	
‘saltatory’	impulse	propagation	(Geren	and	Raskind,	1953),	myelin	is	also	essential	
for	the	proper	development	and	function	of	the	vertebrate	nervous	system.	While	
optimizing	the	electrical	activity	of	axons,	myelin	also	clearly	provides	trophic	and	
metabolic	support	to	ensheathed	axons	(Nave,	2010).	
	 In	order	for	myelin	production	to	occur,	either	during	development	or	after	
injury,	oligodendrocytes	must	progress	through	a	well-characterized	series	of	
differentiation	steps.	Oligodendrocyte	precursor	cells	(OPCs)	in	the	developing	
brain	and	spinal	cord	are	derived	from	multiple,	distinct	cellular	foci	during	late	
embryonic	gestation	(Rowitch	and	Kriegstein,	2010).	OPCs	are	identified	
histologically	by	their	expression	of	the	platelet-derived	growth	factor	receptor	
alpha	(PDGFRα)	and	the	NG2	proteoglycan.	OPCs	are	highly	migratory	and	
																																																								
1	Portions	of	this	chapter	are	reproduced	with	permission	from	Ahrendsen	JT,	
Macklin	WB	(2013)	Signaling	mechanisms	regulating	myelination	in	the	central	
nervous	system.	Neurosci	Bull	29:199–215.	
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proliferative	during	late	embryonic	and	early	postnatal	development	in	order	to	
populate	the	entirety	of	the	CNS	(de	Castro	and	Bribián,	2005;	Moyon	et	al.,	2015).	
Once	located	at	their	final	destination,	some	OPCs	persist	into	adulthood	while	
others	differentiate	into	myelin-producing	oligodendrocytes.	
	 The	differentiation	of	OPCs	into	oligodendrocytes	is	regulated	both	spatially	
and	temporally.	Both	intrinsic	and	extrinsic	factors	regulate	oligodendrocyte	
differentiation,	including	protein	kinases/phosphatases,	transcription	factors,	
soluble	growth	factors,	the	extracellular	matrix,	and	neuronal	activity/cues	(Huang	
et	al.,	2013).	Furthermore,	cells	early	in	the	differentiation	program,	called	pre-
myelinating	oligodendrocytes,	will	undergo	programmed	cell	death	if	unable	to	find	
an	appropriate	substrate	for	myelination	and/or	do	not	receive	the	necessary	
differentiation	signals	(Trapp	et	al.,	1997).	While	the	loss	of	pre-myelinating	
oligodendrocytes	is	a	normal	part	of	CNS	development,	differentiation	failure	is	a	
pathological	feature	in	multiple	sclerosis	(MS),	the	most	common	demyelinating	
disease	of	the	CNS	(Chang	et	al.,	2002).	Thus,	promoting	oligodendrocyte	
differentiation	represents	a	promising	target	for	promoting	recovery	after	
demyelinating	injury	(Franklin	and	ffrench-Constant,	2008).	Those	cells	which	find	
axonal	substrates	for	myelination	and	receive	the	necessary	input	will	go	on	to	
become	actively	myelinating	oligodendrocytes.	
The	process	of	myelination	involves	enormous	energy	expenditure	for	
massive	membrane	biogenesis	to	generate	concentric,	spiral	wraps	of	myelin	
around	axons	(Pfeiffer	et	al.,	1993).	In	mammals,	this	process	occurs	in	large	part	
during	postnatal	development	(Rorke	and	Riggs,	1969;	Sowell	et	al.,	2003;	de	Castro	
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and	Bribián,	2005;	Bradl	and	Lassmann,	2010;	Moyon	et	al.,	2015)	and	is	modulated	
by	electrical	activity	(Zalc	and	Fields,	2000;	Wake	et	al.,	2011)	as	well	as	axon-
derived	molecular	signals	(Taveggia	et	al.,	2010).	The	maturation	of	axons	and	their	
long-term	survival	depend	on	the	presence	of	myelin	(Nave,	2010).	In	turn,	the	
proliferation,	migration,	survival,	and	differentiation	of	myelinating	glia	require	
axon-derived	signals	(Nave	and	Trapp,	2008),	and	the	long-term	maintenance	of	the	
myelin	sheath	also	depends	on	axonal	signals	(Bremer	et	al.,	2010).	Thus,	there	
exists	extensive	bidirectional	signaling	between	oligodendrocytes	and	axons.	
It	is	well-established	that	myelin	thickness	is	directly	related	to	axon	
diameter	(Donaldson	and	Hoke,	1905;	Friede,	1972).	Optimal	conduction	by	
myelinated	axons	is	achieved	by	adjusting	the	length	and	thickness	of	the	myelin	
sheath	to	the	axon	diameter	(Waxman,	1997).	An	axon	with	either	too	little	or	too	
much	myelin	will	not	function	optimally.	Therefore,	precise	molecular	mechanisms	
exist	that	regulate	myelin	production.	After	producing	the	requisite	amount	of	
myelin,	the	actively	myelinating	oligodendrocyte	transitions	into	a	myelin	
maintenance	stage.	While	still	capable	of	producing	myelin,	the	rate	of	production	
and	turnover	of	myelin	decreases	substantially	(Quarles	et	al.,	2006).	Recent	single	
cell	RNA-seq	data	suggest	that	there	are	as	many	six	different	subclasses	of	
oligodendrocyte,	including	the	myelinating	oligodendrocyte	and	terminally	
differentiated	postmyelination	oligodendrocyte	(Zeisel	et	al.,	2015).	Little	is	known	
about	these	subclasses	of	mature	oligodendrocytes	and	what	regulates	the	
transition	from	a	myelinating	cell	to	a	postmyelinating	cell.	
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Akt	signaling	
	
	 Akt	(also	known	as	Protein	Kinase	B)	is	a	serine/threonine	protein	kinase	is	
a	downstream	effector	of	the	lipid	kinase	phosphatidylinositol	3-kinase	(PI3K)	and	
an	upstream	activator	of	mammalian	target	of	rapamycin	(mTOR)	(Figure	1-1)	
(Burgering	and	Coffer,	1995;	Franke	et	al.,	1995).	Akt	signaling	regulates	many	
aspects	of	cellular	function,	including	proliferation,	cell	growth,	survival,	
metabolism,	and	migration	(Yang	et	al.,	2010a).	Thus,	it	is	not	surprising	that	
disrupted	Akt	signaling	is	often	a	cause	of	cancer	in	many	tissues.	However,	Akt	
signaling	is	a	vital	part	of	normal	cellular	function	so	understanding	how	it	is	
regulated	offers	unique	insight	into	controlling	the	action	of	Akt	for	therapeutic	
purposes.	
The	mammalian	genome	encodes	three	separate	genes	for	Akt.	The	rate	
limiting	step	in	activating	the	kinase	activity	of	Akt	is	binding	of	the	lipid	second	
messenger	phosphatidylinositol	(3,4,5)-triphosphate	(PIP3)	(generated	by	activated	
PI3K	in	response	to	growth	factors	and	other	extracellular	stimuli)	to	the	pleckstrin	
homology	(PH)	domain	of	Akt	and	the	subsequent	translocation	of	Akt	to	the	plasma	
membrane	(Kandel	and	Hay,	1999).	Akt	activation	is	promoted	by	phosphorylation	
at	threonine	308	by	protein	dependent	kinase-1	and	mTOR	complex	2	(mTORC2)	at	
serine	473	(Alessi	et	al.,	1996;	Sarbassov	et	al.,	2005;	Jacinto	et	al.,	2006).	Both	
phosphorylation	events	are	necessary	for	full	activation	of	Akt.		
Akt	kinase	activity	has	many	cellular	targets	(Kim	et	al.,	2005).	In	particular,	
Akt	directly	phosphorylates	and	inactivates	tuberous	sclerosis	complex	2	(TSC2)	
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(Manning	et	al.,	2002).	TSC2	is	an	upstream	inhibitor	of	mTOR,	thus	Akt	activity	
promotes	mTOR	activation	through	inhibition	of	TSC2	(Inoki	et	al.,	2002).	mTOR	can	
then	activate	proteins	such	as	4E-BP1	and	S6-kinase	in	order	to	regulate	protein	
synthesis	and	cell	growth	(Hay	and	Sonenberg,	2004).		
Regulation	of	Akt	signaling	is	accomplished	at	many	levels	by	several	
proteins.	Phosphorylation	events	have	positive	effects	on	Akt	activity,	both	
upstream	on	lipid	second	messengers	and	on	the	Akt	protein.	Therefore,	
downregulation	of	Akt	signaling	is	often	accomplished	at	the	molecular	level	by	
removal	of	phosphate	groups	(dephosphorylation)	by	phosphatases	(Figure	1-1,	2-
1).	PTEN	is	the	classic	negative	regulator	of	Akt	signaling,	which	acts	as	a	lipid	
phosphatase	and	decreases	levels	of	PIP3	by	catalyzing	the	formation	of	PIP2	
(Stambolic	et	al.,	1998).	Signaling	regulators	can	themselves	be	regulated	by	
phosphorylation/dephosphorylation	events	and	interactions	with	scaffolding	
proteins.	For	example,	PTEN	phosphatase	activity	is	upregulated	when	
phosphorylated	at	three	sites	on	its	C-terminal	tail	domain	(S380/T382/T383);	
however	this	also	renders	PTEN	less	stable	(Vazquez	et	al.,	2000).	PTEN	activity	is	
also	upregulated	by	binding	to	certain	scaffolding	proteins	such	as	Nherf	(Takahashi	
et	al.,	2006).	Binding	to	scaffolding	proteins	can	regulate	the	stability	of	other	
proteins	and	can	also	sequester	them	to	certain	subcellular	locations.	The	regulation	
of	Akt	signaling	by	other	phosphatases	is	discussed	more	thoroughly	below	and	in	
Chapter	II.	Finally,	Akt	signaling	can	be	regulated	by	other	post-translational	
modifications,	such	as	ubiquitination,	a	process	by	which	proteins	are	targeted	for	
degradation	(Yang	et	al.,	2010a).	
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Molecular	mechanisms	regulating	myelination:	PNS	
	
	 The	molecular	mechanisms	regulating	myelination	in	the	peripheral	nervous	
system	(PNS)	by	myelinating	Schwann	cells	are	well	studied	and	provide	important	
insight	into	potential	mechanisms	governing	myelination	in	the	CNS.	In	the	PNS,	
Figure	1-1.	Schematic	of	Akt	signaling.	Extracellular	ligand	(dark	blue)	
binding	a	transmembrane	receptor	and	activating	the	PI3K/Akt/mTOR	
pathway	(light	blue	icons).	Negative	regulators	indicated	in	red.	Lipid	second	
messengers	PIP2	and	PIP3	indicated	in	yellow.		
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neuregulin	1	(NRG1)	type	III	signaling	from	the	axon	membrane	can	influence	
whether	an	axon	is	myelinated	(Taveggia	et	al.,	2005),	and	the	amount	of	axonal	
NRG1	type-III	regulates	peripheral	myelin	sheath	thickness	(Michailov	et	al.,	2004).	
NRG1	signaling	acts	through	ErbB	receptors	on	Schwann	cells	to	regulate	PNS	
myelination	(Chen	et	al.,	2006).	The	peripheral	hypermyelination	disorder	Charcot-
Marie-tooth	disease	type	1A	results	from	mutations	leading	to	overexpression	of	
ErbB2	and	ErbB3	receptors	(Massa	et	al.,	2006).		
	 NRG1	mediated	activation	of	Schwann	cell	ErbB	receptors	triggers	activation	
of	the	PI3K/Akt	pathway	(Maurel	and	Salzer,	2000),	which	then	signals	though	
mTOR	(Sherman	et	al.,	2012)	to	promote	myelination	(Figure	1-1).	The	genetic	
knockout	of	PTEN	from	myelinating	Schwann	cells	artificially	elevates	the	levels	of	
PIP3	concentrations	within	Schwann	cells,	resulting	in	increased	Akt	signaling	and	
myelin	overproduction	(Goebbels	et	al.,	2010;	2012).		
	 While	there	are	signals	that	drive	myelination,	there	must	also	be	
mechanisms	to	counteract,	or	brake,	those	signals	when	the	optimal	amount	of	
myelin	has	been	formed	for	any	given	axon	in	order	to	prevent	deleterious	over	
production	of	myelin.	The	“myelin	brake”	of	the	PNS	was	discovered	using	a	
combination	of	human	genetic	data	along	with	transgenic	mouse	technology.	
Myotubularin-related	protein	2	(MTMR2)	was	identified	as	the	genetic	cause	of	
Charcot-Marie-Tooth	disease	4B,	another	hypermyelinating	disorder	of	the	PNS	
(Bolino	et	al.,	2000;	Bonneick	et	al.,	2005).	This	led	to	the	discovery	that	the	
scaffolding	protein	Dlg1	(mammalian	discs	large	homolog	1)	interacts	with	MTMR2	
to	stabilize	PTEN	in	order	to	downregulated	PI3K/Akt	signaling	in	Schwann	cells	
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after	the	appropriate	amount	of	myelin	had	been	formed,	thereby	decreasing	myelin	
production	(Cotter	et	al.,	2010).	Furthermore,	there	are	multiple	levels	of	regulatory	
control	over	myelination	as	Dlg1	acts	as	a	transient	negative	regulator	of	
myelination	and	also	serves	to	increase	the	expression	of	DDIT4	(a	known	negative	
regulator	of	mTOR	(Ellisen,	2005))	in	order	to	provide	sustained	downregulation	of	
myelin	production	(Noseda	et	al.,	2013).	Therefore,	in	the	PNS,	Dlg1	and	DDIT4	
downregulate	Akt/mTOR	signaling	and	halt	the	myelination	process	at	the	
appropriate	time,	thereby	ensuring	optimal	electrical	conductance	along	myelinated	
axons	and	protecting	against	pathological	membrane	overproduction.	
	
Molecular	mechanisms	regulating	myelination:	CNS	
	
The	role	of	NRG1/ErbB	signaling	in	the	CNS	is	less	clear.	Neuregulins	
mediate	survival	and	differentiation	of	cultured	oligodendrocyte	progenitor	cells	
(OPCs)	(Canoll	et	al.,	1996;	Flores	et	al.,	2000),	and	spinal	cord	explant	studies	
demonstrate	the	requirement	for	NRG1	signaling	in	oligodendrocyte	development	
(Vartanian	et	al.,	1999).	Other	studies	suggest	that	while	axonal	NRG1	does	not	
direct	initial	oligodendrocyte	differentiation,	it	promotes	myelination	in	some	CNS	
areas	(Taveggia	et	al.,	2008).	Similar	to	the	PNS,	ErbB2	signaling	has	also	been	
shown	to	positively	regulate	terminal	oligodendrocyte	differentiation	and	
myelination	in	vivo	(Park	et	al.,	2001;	Kim	et	al.,	2003).	ErbB4	signaling	in	
oligodendrocytes	is	quite	complex.	The	complete	loss	of	ErbB4	signaling	in	neural	
tube	explants	increases	the	number	of	differentiated	oligodendrocytes	(Sussman	et	
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al.,	2005),	whereas	the	in	vivo	expression	of	a	dominant	negative	ErbB4	that	binds	
NRG1,	but	cannot	signal	in	oligodendrocytes,	results	in	fewer	oligodendrocytes	and	
reduced	myelin	thickness	of	CNS	axons	(Roy	et	al.,	2007).	While	these	studies	
suggest	at	least	regional	CNS	regulation	of	oligodendrocyte	development	or	
myelination	by	NRG1,	mice	with	complete	NRG1	knockout	or	elimination	of	both	
ErbB3	and	ErbB4	receptors	in	oligodendrocytes	have	normal	CNS	myelination,	
indicating	that	these	factors	are	not	required	for	normal	CNS	myelination	
(Brinkmann	et	al.,	2008).	On	the	other	hand,	that	same	study	demonstrated	that	
overexpression	of	either	NRG1	type-I	or	type-III	could	induce	CNS	
hypermyelination.	Thus,	NRG1	clearly	impacts	some	elements	of	CNS	myelination.	
Similar	to	Schwann	cells,	PI3K/Akt	signaling	in	oligodendrocytes	is	activated	
by	neuregulins	(Flores	et	al.,	2000;	Hu	et	al.,	2006;	Luo	et	al.,	2011).	The	genetic	
overexpression	of	a	constitutively	active	form	of	Akt	in	oligodendrocytes	(Akt-DD)	
causes	CNS	hypermyelination,	without	affecting	oligodendrocyte	differentiation,	
proliferation,	or	survival	(Flores	et	al.,	2008).	Hypermyelination	in	these	animals	is	
driven	by	Akt	signaling	through	mTOR,	and	is	reversible	upon	treatment	with	the	
mTOR	inhibitor	rapamycin	(Narayanan	et	al.,	2009).	Furthermore,	the	lack	of	myelin	
observed	in	the	BACE1	null	mouse,	which	lacks	a	neuregulin	cleavage	enzyme,	can	
be	rescued	by	Akt-DD	overexpression	(Hu	et	al.,	2006;	2013).	In	other	studies,	
conditional	expression	of	the	mTOR	activator	Rheb	(a	downstream	effector	of	Akt)	
in	neural	progenitors	has	been	shown	to	promote	myelination	in	the	brain,	while	
conditional	Rheb	knockout	from	the	same	cells	inhibits	myelination	(Zou	et	al.,	
2011).	
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mTOR	function	in	oligodendrocytes,	like	NRG1/ErbB	signaling,	is	also	quite	
complicated.	mTOR	is	required	for	the	developmentally	regulated	expression	of	
several	myelin	proteins	and	lipid	biogenesis	enzymes	such	as	those	driving	
cholesterol	and	fatty	acid	synthesis	(Tyler	et	al.,	2011).	The	conditional	knockout	of	
the	entire	mTOR	complex	disrupts	oligodendrocyte	differentiation	and	the	extent	of	
myelination	in	a	region	specific	manner	(Wahl	et	al.,	2014).	Raptor	dependent	
mTOR	complex	1	serves	as	a	positive	regulator	of	myelination	and	the	conditional	
knockout	of	Raptor	also	causes	region	specific	myelin	abnormalities,	even	in	the	
presence	of	functional	mTOR	complex	2	(Bercury	et	al.,	2014).	Together,	these	
results	provide	strong	evidence	that	Akt	signaling	through	mTOR	has	significant	
impact	on	myelin	formation	and	could	represent	a	master	regulator	of	myelination	
in	the	CNS.		
Again,	similar	to	that	observed	in	the	PNS,	the	conditional	knockout	of	PTEN	
from	oligodendrocytes	during	development	causes	dramatic	CNS	hypermyelination	
(Harrington	et	al.,	2010)	and	overproduction	of	myelin	can	be	induced	after	active	
myelination	has	ceased	by	deleting	PTEN	from	oligodendrocytes	in	adulthood	
(Goebbels	et	al.,	2010).	However,	unlike	in	PNS,	there	are	no	known	human	diseases	
or	conditions	in	which	over	production	of	myelin	in	the	CNS	is	a	distinguishing	
pathological	feature.		Furthermore,	proteins	such	as	MTMR2,	Dlg1,	and	DDIT4	are	
expressed	at	very	low	levels	in	the	CNS	and	do	not	show	an	expression	profile	that	
resembles	that	of	a	“myelin	brake”,	as	they	do	in	the	PNS	(Cotter	et	al.,	2010;	Noseda	
et	al.,	2013;	Zhang	et	al.,	2014).	Therefore,	the	identification	of	the	“myelin	brake”	in	
the	CNS	remains	as	a	significant	unanswered	question.		
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Oligodendrocytes,	demyelination	and	multiple	sclerosis	
	
Disruption	of	oligodendrocytes	and	the	axon-myelin	relationship	is	seen	in	
many	congenital	and	acquired	neurological	diseases	and	conditions,	including	
genetic	leukodystrophies,	perinatal	hypoxia/ischemia,	stroke,	and	MS.	The	most	
common	cause	of	neurological	disability	in	young	adults,	MS	is	characterized	by	CNS	
demyelination	induced	by	inflammation	and	immune	responses.		Acute	
demyelinating	episodes	result	in	neurological	impairment	that	is	generally	followed	
by	some	functional	recovery	as	the	inflammation	resolves.	Recovery	is	primarily	due	
to	myelin	regeneration	of	demyelinated	axons.	However,	permanent	disability	is	
eventually	seen	in	MS,	resulting	from	axonal	transection	after	chronic	demyelination	
or	other	pathologies	(Trapp	et	al.,	1998),	although	axonal	damage	can	occur	at	the	
same	time	as	demyelination	(Trapp	and	Nave,	2008).	Clearly,	investigating	the	
mechanisms	regulating	axon-myelin	interactions	is	pivotal	in	order	to	improve	
treatments	of	demyelinating	diseases	such	as	MS.	
Currently,	the	only	Food	and	Drug	Administration	(FDA)	approved	
medications	for	treating	MS	are	immune	modulating	agents,	which	help	to	prevent	
immune	and	inflammatory	attacks	during	the	relapsing-remitting	stage	of	MS.	
However,	none	of	these	agents	is	effective	in	treating	the	progressive	phase	of	the	
disease	that	results	from	accumulated	axon	damage.	An	additional	approach	to	
treating	this	disease	would	be	to	enhance	the	endogenous	repair	processes	that	
occur	naturally	after	acute	demyelination.	Remyelination	occurs	during	early	stages	
of	MS	and,	while	rarely	complete,	allows	for	some	functional	recovery	(Patrikios	et	
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al.,	2006;	Franklin	et	al.,	2012).	However,	after	multiple	episodes	of	demyelination,	
repair	fails,	resulting	in	progressive	neurodegeneration	(Franklin,	2002).	The	
process	of	remyelination	shares	many	features	with	developmental	myelination	
(Fancy	et	al.,	2011a).	Therefore,	a	thorough	understanding	of	the	mechanisms	
regulating	developmental	myelination	may	help	target	remyelination	
therapeutically,	promoting	functional	recovery	and	preventing	MS	progression.	
Currently,	drug	designers	have	been	unsuccessful	in	creating	pharmaceuticals	that	
promote	remyelination	in	human	patients.	
The	signaling	mechanisms	regulating	remyelination	are	poorly	understood.	
Although	conditional	knockout	of	PTEN	from	oligodendrocytes	causes	
developmental	hypermyelination,	it	has	no	effect	on	remyelination	(Harrington	et	
al.,	2010).	However,	in	wild	type	mice	treated	with	rapamycin,	oligodendrocyte	
differentiation	and	remyelination	are	delayed	after	cuprizone	induced	
demyelination,	suggesting	that	mTOR	signaling	is	important	in	the	remyelination	
process	(Sachs	et	al.,	2014).	
While	repeated	episodes	of	de/remyelination	affect	an	oligodendrocyte’s	
ability	to	repair,	there	also	exist	age-associated	differences	influencing	
remyelination	efficiency	(Franklin	and	ffrench-Constant,	2008).	Compared	to	adult	
mice,	older	mice	are	less	efficient	and	juvenile	mice	are	more	efficient	at	repairing	a	
demyelinated	lesion	(Shields	et	al.,	1999;	Pfeifenbring	et	al.,	2015).	Aging	affects	the	
intrinsic	ability	of	an	OPC	to	differentiate	after	a	demyelination	injury	(Shen	et	al.,	
2008).	There	are	also	circulating	factors	in	the	blood	that	affect	remyelination	
efficiency,	such	that	an	old	mouse	exposed	to	a	youthful	circulation	improves	the	
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older	mouse’s	ability	to	remyelinate	(Ruckh	et	al.,	2012).	Thus,	biological	age	has	
both	cell	intrinsic	and	extrinsic	influences	on	remyelination.	
	
Oligodendrocytes	and	stroke	
	
An	ischemic	stroke	is	generally	caused	by	an	obstruction	of	blood	flow	to	an	
area	of	the	brain,	thereby	disrupting	the	delivery	of	nutrients	and	oxygen	as	well	as	
the	elimination	of	waste.	Without	timely	restoration	of	blood	flow,	the	infarcted	
tissue	becomes	necrotic,	resulting	in	permanent	neurological	disability	or	death.	In	
addition,	even	the	restoration	of	blood	flow	causes	production	of	reactive	oxygen	
species,	which	contribute	additional	damage	from	significant	oxidative	stress	to	
injured	tissue	(Allen	and	Bayraktutan,	2009).	
	 The	human	brain	consists	of	nearly	equal	proportions	of	gray	matter,	which	
contains	neuronal	cell	bodies,	as	well	as	white	matter,	consisting	primarily	of	
oligodendrocytes	and	myelinated	axons	(Zhang	and	Sejnowski,	2000).	White	matter	
also	has	a	metabolic	rate	that	is	only	modestly	less	than	that	of	gray	matter	
(Nishizaki	et	al.,	1988).	Furthermore,	injury	to	myelinated	axons	in	one	region	of	the	
brain	can	lead	to	secondary	injury	via	Wallerian	degeneration	in	distal	parts	of	the	
brain	where	the	neuronal	cell	body	is	located	(Thomalla	et	al.,	2005;	Kalesnykas	et	
al.,	2008).	Therefore,	white	matter	injury	is	a	significant	component	of	cerebral	
ischemia	(Matute	et	al.,	2013).	Despite	the	deleterious	effects	of	ischemia	on	white	
matter	regions	of	the	brain,	most	stroke	research	is	disproportionately	focused	on	
the	gray	matter	aspects	of	stroke.	
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	 Oligodendrocytes	are	known	to	be	sensitive	to	stroke,	and	pathological	
features	of	oligodendrocyte	injury	after	experimental	cerebral	ischemia	have	been	
observed	as	early	as	30	minutes	after	arterial	occlusion	(Pantoni	et	al.,	1996).	In	
addition	to	oligodendrocyte	dysfunction	and	cell	death,	stroke	also	causes	myelin	
loss	and	axon	injury	(Zhou	et	al.,	2013;	Hinman	et	al.,	2015).	These	cellular	
pathologies	result	in	long	term	behavioral	abnormalities,	including	complex	
cognitive	impairment	and	recognition	memory	deficit	(Zhou	et	al.,	2013;	Blasi	et	al.,	
2014).	Therefore,	a	thorough	understanding	of	stroke’s	effects	on	white	matter	and	
oligodendrocytes	is	pivotal	in	developing	better	therapeutic	strategies	to	mitigate	
long-term	damage	and	promote	functional	recovery	after	stroke	(Matute	et	al.,	
2013).	
	 While	white	matter	is	sensitive	to	ischemic	injury,	the	resulting	pathology	is	
dependent	on	the	developmental	age	of	the	injured	brain	(Baltan	et	al.,	2008;	Baltan,	
2009).	Ischemic	injury	in	oligodendrocytes	and	myelinated	axons	is	thought	to	
occur	by	three	interrelated	mechanisms:	ionic	imbalances,	AMPA/kainate	receptor	
mediated	excitotoxicity,	and	oxidative	stress	(Baltan,	2009).	The	relative	
contribution	of	each	of	these	pathological	mechanisms	varies	depending	the	age	at	
which	injury	occurs.		
	 Following	perinatal	hypoxia	ischemia,	late-stage	oligodendrocyte	precursor	
cells	are	selectively	vulnerable,	presumably	to	increased	sensitivity	to	oxidative	
stress	(Back	et	al.,	2002a;	Haynes	et	al.,	2003).	The	loss	of	these	late-stage	OPCs	
results	in	myelination	failure	due	to	arrested	oligodendrocyte	maturation	(Segovia	
et	al.,	2008).	The	long-term	effects	to	survivors	of	perinatal	hypoxic/ischemic	injury	
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include	motor	impairment	(i.e.	cerebral	palsy)	and	a	broad	spectrum	of	cognitive,	
visual,	social,	and	learning	disabilities	(Back	and	Rosenberg,	2014).	
	 In	the	adult,	sequential	events	govern	white	matter	injury	following	stroke	
(Baltan,	2009).	Ionic	imbalances	due	to	reversal	of	sodium/calcium	exchangers	
must	occur	before	glutamate	mediated	excitotoxicity	takes	place	(Matute,	2011).	
Injury	can	be	prevented	in	experimental	models	by	removal	of	extracellular	calcium,	
and	application	of	exogenous	glutamate	on	its	own	is	not	sufficient	to	cause	white	
matter	injury	(Tekkök	et	al.,	2007).	Furthermore,	excess	glutamate	interferes	with	
cysteine	uptake,	thereby	reducing	cellular	glutathione	stores	and	increasing	
oxidative	stress	to	oligodendrocytes	(Oka	et	al.,	1993).	
	 The	aging	brain	also	responds	differently	to	ischemic	injury.	Whereas	ionic	
imbalances	are	a	necessary	prerequisite	for	glutamate	induced	excitotoxicity	
following	stroke	in	adult	animals	(Tekkök	et	al.,	2007),	in	the	aged	mouse,	
excitotoxicity	occurs	independently	of	ionic	imbalances	(Baltan	et	al.,	2008).	
Similarly,	advanced	age	has	a	profound	impact	on	the	outcome	of	white	matter	
stroke,	with	increased	and	prolonged	oligodendrocyte	death	and	oxidative	damage	
occurring	in	aged	compared	to	adult	mice	(Rosenzweig	and	Carmichael,	2013).		
	 While	not	as	common	as	stroke	occurring	later	in	adulthood,	pediatric	stroke	
is	thought	to	affect	more	than	1,000	children	in	the	United	States	each	year,	with	
likely	more	cases	going	undiagnosed	and/or	misdiagnosed	(Tsze	and	Valente,	
2011).	The	lack	of	recognition	of	pediatric	stroke	could	be	attributed	to	the	poor	
understanding	that	currently	exists	regarding	this	condition.	The	recent	
development	of	an	experimental	model	of	pediatric	stroke	is	helping	address	this	
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issue	(Herson	et	al.,	2013).	Together,	these	studies	suggest	that	strategies	to	protect	
white	matter	damage	after	ischemic	injury	may	be	substantially	different,	
depending	on	the	developmental	age	of	the	injured	tissue.		
	 	
Hypotheses	
	
First,	this	thesis	extends	the	studies	on	the	regulation	of	CNS	myelination,	
with	an	added	focus	on	the	inhibitory	signals	that	downregulate	the	myelination	
process	after	axons	have	been	appropriately	wrapped.	A	major	question	in	the	field	
of	oligodendrocyte	biology	is	how	an	oligodendrocyte	signals	to	itself	to	cease	
myelin	production.	I	hypothesize	that	negative	regulators	of	Akt	signaling	in	
oligodendrocytes	downregulate	myelination,	thereby	shifting	actively	myelinating	
oligodendrocytes	to	a	myelin	maintenance	phenotype.	I	identified	the	protein	
tyrosine	phosphatase	Shp2	as	a	putative	myelin	brake	in	the	CNS	and	using	
transgenic	mouse	technology,	I	examine	the	role	of	oligodendrocyte	Shp2	as	a	cell	
autonomous	regulator	of	CNS	myelination.		
	 Actively	myelinating	oligodendrocytes	are	enriched	in	the	late	pediatric	
brain	and	the	late	juvenile	period	is	unique	in	development	as	it	is	the	time	of	
maximal	myelination	(Foran	and	Peterson,	1992;	Paus	et	al.,	1999).	During	this	time,	
actively	myelinating	oligodendrocytes	generate	massive	amounts	of	myelin	surface	
area,	have	very	high	metabolic	rates,	and	consume	high	levels	of	oxygen	and	ATP	
(Harris	and	Attwell,	2012).	Thus,	models	pediatric	stroke	allow	for	detailed	analysis	
of	the	ischemic	effects	specifically	on	actively	myelinating	oligodendrocytes.	
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Furthermore,	direct	comparisons	of	white	matter	injury	between	adult	and	
pediatric	animals	using	the	same	experimental	procedures	have	not	been	
performed.	I	hypothesize	that	actively	myelinating	oligodendrocytes	in	the	late	
pediatric	brain	are	particularly	vulnerable	to	ischemic	injury.	In	order	to	test	this	
hypothesis,	I	examined	the	glial	responses	following	experimentally-induced	stroke	
in	juvenile	mice	and	compared	these	responses	to	adult	mice	given	the	same	injury.	
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CHAPTER	II	
IDENTIFICATION	OF	A	PUTATIVE	MYELIN	BRAKE	IN	THE	CENTRAL	NERVOUS	
SYSTEM2	
	
Summary	
	
The	coordinated	production	of	myelin	is	required	for	proper	nervous	system	
development	and	function.	Myelination	is	tightly	regulated	and	myelin	sheath	
thickness	is	linked	to	the	caliber	of	the	myelinated	axon.	Clearly	signaling	between	
axons	and	myelinating	glia	must	establish	the	amount	of	myelin	needed,	i.e.,	when	
the	ensheathing	cell	should	shift	from	active	myelination	to	myelin	maintenance.	
The	current	studies	investigate	the	molecular	mechanisms	that	control	CNS	
myelination.	Akt	signaling	is	important	for	driving	CNS	myelin	production,	and	
transgenic	mice	that	express	constitutively	active	Akt	(Akt-DD)	in	oligodendrocytes	
are	unable	to	stop	active	myelination,	thereby	overriding	the	natural	braking	
mechanisms	of	CNS	myelination.	Thus,	this	system	potentially	allows	for	the	
identification	of	the	“myelin	brake”	in	the	CNS.	We	hypothesize	that	negative	
regulator(s)	of	Akt	signaling	may	serve	as	the	myelin	brake	in	the	CNS.	Using	a	
candidate-based	approach	to	examine	the	developmental	expression	profiles	of	
putative	Akt	signaling	regulators	in	both	wild	type	and	Akt-DD	mice,	we	identified	
the	protein	tyrosine	phosphatase	Shp2	as	a	potential	myelin	brake	candidate.		
																																																								
2	Portions	of	this	chapter	are	reproduced	with	permission	from	Ahrendsen	JT,	
Macklin	WB	(2013)	Signaling	mechanisms	regulating	myelination	in	the	central	
nervous	system.	Neurosci	Bull	29:199–215.	
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Introduction	
	
The	production	of	myelin,	the	ensheathing	membrane	that	is	essential	for	
proper	nervous	system	development	and	function,	is	tightly	regulated.	The	
thickness	of	the	myelin	sheath	correlates	closely	with	the	caliber	of	the	myelinated	
axon	(Friede,	1972).	This	correlation	suggests	that	bidirectional	interactions	
between	axons	and	myelinating	glia	determine	the	amount	of	myelin	that	is	
generated.	Thus,	iter-	and	intracellular	signals	must	direct	the	increase	in	myelin	
gene	expression	required	for	proper	myelination	and	also	establish	when	the	
ensheathing	cell	should	decrease	active	myelin	production	and	shift	to	myelin	
maintenance.	Studies	in	the	peripheral	nervous	system	(PNS)	have	shown	that	
myelin	thickness	is	driven	by	neuregulin-1	type	III	(NRG1)	expression	on	axons	
acting	through	ErbB	receptors	on	myelinating	Schwann	cells	to	increase	Akt	
signaling	(Michailov	et	al.,	2004).	Akt	signaling	through	mTOR	is	necessary	for	
myelin	sheath	production	by	Schwann	cells	(Sherman	et	al.,	2012).	The	Dlg1	
scaffolding	protein	is	comparably	regulated	by	axonal	NRG1,	but	serves	as	a	
transient	brake	to	this	process	by	stabilizing	PTEN,	a	lipid	phosphatase,	whose	
activity	then	downregulates	Akt	signaling	(Cotter	et	al.,	2010).	Sustained	
downregulation	of	PNS	myelination	is	accomplished	by	DDIT4,	a	negative	regulator	
of	mTOR	signaling	(Noseda	et	al.,	2013).		
20	
In	the	central	nervous	system	(CNS),	regulation	of	myelination	appears	more	
complex	than	in	the	PNS.	The	neuregulin/ErbB	receptor	signaling	system	is	
sufficient,	but	not	necessary,	to	regulate	CNS	myelination	(Brinkmann	et	al.,	2008).	
Akt	signaling	through	mTOR	in	oligodendrocytes,	the	myelinating	cells	of	the	CNS,	is	
a	prominent	signaling	axis	that	drives	active	myelin	production	(Flores	et	al.,	2008;	
Figure	2-1.	Regulation	of	Akt	signaling.	Extracellular	ligand	(dark	blue)	
binding	a	transmembrane	receptor	and	activating	the	PI3K/Akt	pathway	
(light	blue	icons).	Lipid	second	messengers	PIP2	and	PIP3	indicated	in	yellow.	
Negative	regulators	indicated	in	red.	Blunted	arrows	indicate	inhibition.	
Dashed	line	indicates	indirect	regulation.	
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Narayanan	et	al.,	2009)	and	could	serve	as	a	master	regulator	of	myelination.	
Transgenic	mice	that	overexpress	constitutively	active	Akt	in	oligodendrocytes	
(Akt-DD)	remain	actively	myelinating	throughout	the	animals	life,	resulting	in	
pathological	overproduction	of	myelin	(Flores	et	al.,	2008).	In	wild	type	mice,	by	
contrast,	the	majority	of	active	myelination	in	the	brain	occurs	during	the	third	and	
fourth	week	of	postnatal	life.	Thus,	the	natural	braking	mechanisms	of	CNS	
myelination	have	been	overridden	in	these	Akt-DD	mice	and	can	be	used	as	a	
powerful	tool	for	identifying	putative	negative	regulators	of	myelination.	We	
hypothesize	that	negative	regulation	of	active	myelin	production	is	accomplished	by	
inhibiting	Akt	signaling	in	oligodendrocytes.	
The	conditional	knockout	of	PTEN	from	oligodendrocytes	also	causes	over	
production	of	myelin	in	the	CNS	by	upregulating	Akt	signaling	(Goebbels	et	al.,	2010;	
Harrington	et	al.,	2010).	However,	unlike	the	situation	in	the	PNS,	there	are	no	
known	human	disorders	of	myelin	overproduction	in	the	CNS.	Therefore,	the	
“myelin	brake”	of	the	CNS	has	yet	to	be	identified.	While	PTEN	is	a	potential	
candidate,	the	braking	mechanisms	that	exist	in	the	PNS	(Dlg1,	DDIT4)	are	not	
expressed	at	levels	relevant	enough	to	regulate	myelination	in	the	CNS.	
The	current	study	extends	these	studies	on	the	regulation	of	CNS	
myelination,	with	an	added	focus	on	the	inhibitory	proteins	that	downregulate	Akt	
signaling	(Figure	2-1).	We	examined	the	developmental	expression	profiles	of	
candidate	genes	expressed	by	oligodendrocytes	that	are	implicated	in	
downregulating	Akt	signaling.	Of	the	candidate	genes	screened	here,	the	protein	
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tyrosine	phosphatase	Shp2	best	fit	our	prediction	of	a	putative	“myelin	brake”	of	the	
CNS.	
	
Experimental	procedures	
	
Materials.	Antibodies	were	obtained	from	Cell	Signaling	Technology	(GAPDH,	
PTEN,	phospho-PTEN	S380/T382/T383,	Shp1),	Abcam	(Shp2),	and	Bethyl	
Laboratories	(PHLPP).	The	following	Taqman	probes	were	used	for	qPCR	analysis:	
PTEN	(Mm00477208_m1),	PHLPP	(Mm01295850_m1),	Shp1/PTPN6	
(Mm00469153_m1),	Shp2/PTPN11	(Mm00448434_m1),	Ship-1/Inpp5d	
(Mm00494987_m1),	Ship-2/Inppl1	(Mm00802853_m1),	and	GAPDH	
(Mm99999915_g1).	
	
Animals.	All	animal	experiments	were	performed	in	compliance	with	
approved	policies	of	the	University	of	Colorado	School	of	Medicine.	Mice	expressing	
constitutively	active	Akt	in	PLP	expressing	cells	(Flores	et	al.,	2008)	and	wild	type	
littermates	were	anesthetized	with	isoflurane	and	the	corpus	callosum	was	
microdissected,	flash	frozen	in	liquid	nitrogen,	and	stored	at	-80°C.		
	
Western	blots.	Corpus	callosum	protein	lysates	were	prepared	by	
homogenization	in	RIPA	buffer	supplemented	with	protease	inhibitor	tablet	(Roche)	
and	phosphatase	inhibitor	cocktail	(CalBiochem).	20μg	of	protein	was	separated	(4-
20%	SDS-PAGE,	BIO-RAD)	and	transferred	to	a	polyvinylidene	fluoride	(PVDF)	
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membrane.	Membranes	were	blocked	in	5%	BSA	in	TBS	and	incubated	with	the	
following	primary	antibodies:	PTEN,	1:1000;	phospho-PTEN	(S380/T382/T383),	
1:1000;	PHLPP,	1:2500;	GAPDH,	1:5000;	Shp2,	1:1000;	Shp1,	1:1000.	Membranes	
were	washed,	incubated	with	the	appropriate	secondary	antibody	(LI-COR),	and	
imaged/quantified	using	an	Odyssey	Infrared	Imaging	System	(LI-COR).	GAPDH	was	
used	as	a	loading	control.	Three	animals	per	group	were	used	for	protein	expression	
analysis.	Group	means	were	normalized	to	P7	WT.	
	
Quantitative	real	time	polymerase	chain	reaction	(qPCR).	RNA	extraction	
using	TRIzol	Reagent	(Life	Technologies)	and	cDNA	synthesis	were	performed	as	
described	previously	(Bercury	et	al.,	2014).	All	qPCR	experiments	were	performed	
using	Taqman	probes	on	a	StepOnePlus	Real	Time	PCR	System	(Applied	
Figure	2-2.	Dynamics	of	myelin	formation	during	development	in	WT	
and	Akt-DD	mice.	Active	myelination	in	the	brains	of	WT	animals	occurs	
primarily	during	the	3rd	and	4th	weeks	of	postnatal	life	(light	blue),	after	
which	active	myelin	production	slows	to	maintain	steady	amounts	of	myelin	
(dark	blue).	In	the	Akt-DD	mouse,	active	myelination	continues	throughout	
the	animal’s	life	(red),	never	transitioning	to	a	maintenance	phase.	
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Biosciences),	according	to	manufacturer’s	instructions.	At	least	three	animals	per	
group	were	used	for	gene	expression	analysis	and	each	sample	was	run	in	triplicate.	
The	delta(delta(Ct))	method	was	used	to	assess	expression	changes,	using	GAPDH	
as	an	internal	control.	All	samples	were	run	simultaneously	and	gene	expression	for	
each	sample	was	normalized	to	the	average	of	three	P7	WT	samples.	
	
Statistical	analysis.	All	statistical	analyses	were	performed	using	unpaired	
Student’s	t-tests.	Statistical	significance	was	observed	at	P	<	0.05.		
	
Results	
	
Expectations	of	a	putative	myelin	brake.	We	examined	the	expression	profiles	
of	mRNA	and	protein	levels	of	putative	negative	regulators	of	Akt	signaling	that	are	
expressed	by	oligodendrocytes	during	postnatal	development	in	isolated	corpus	
callosum	from	wild-type	(WT)	and	hypermyelinating	Akt-DD	mice.	In	the	PNS,	the	
myelin	brakes	Dlg1	and	DDIT4	are	upregulated	in	a	negative	feedback	mechanism,	
Table	2-1.	Expected	developmental	profile	of	a	CNS	myelin	brake.	
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where	protein	levels	are	increased	as	myelination	peaks.	Thus,	our	first	expectation	
was	that	the	expression	of	a	potential	‘myelination	brake’,	i.e.,	the	signaling	system	
that	shifts	the	oligodendrocyte	from	active	myelination	to	myelin	maintenance,	
would	peak	in	WT	mice	as	active	myelination	comes	to	an	end	and	would	decrease	
to	steady-state	levels	during	adulthood,	when	myelin	maintenance	is	the	
predominant	oligodendrocyte	phenotype	(Figure	2-2,	Table	2-1).	In	Akt-DD	mice,	in	
which	active	myelination	continues	throughout	the	animal’s	lifetime	(Flores	et	al.,	
2008;	Narayanan	et	al.,	2009),	the	myelin	brake	seems	to	have	been	overridden.	
Therefore,	our	second	expectation	was	that	in	Akt-DD	mice,	we	would	observe	a	
continual	increase	in	expression	of	proteins	that	might	act	as	a	myelin	brake	
throughout	development,	in	an	effort	to	curb	the	continuous	
myelin	production	in	these	mice	(Figure	2-2,	Table	2-1).	
	
Developmental	expression	profiles	of	PTEN	and	PHLPP	phosphatases.	Because	
of	it’s	predominant	role	in	the	negative	regulation	of	PNS	myelination	(Cotter	et	al.,	
2010),	as	well	as	its	effect	when	genetically	deleted	from	oligodendrocytes	
(Goebbels	et	al.,	2010;	Harrington	et	al.,	2010),	we	first	examined	PTEN	using	this	
system.	However,	the	expression	profile	of	PTEN	did	not	fit	either	of	the	
expectations	described	above	(Figure	2-3).	PTEN	mRNA	expression	in	white	matter	
samples	from	WT	and	Akt-DD	mice	remained	relatively	unchanged	throughout	
development	and	into	adulthood,	and	did	not	differ	between	WT	and	Akt-DD	mice	
(Figure	2-3A).	At	the	protein	level,	PTEN	expression	was	highest	at	postnatal	day	7		
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Figure	2-3.	Developmental	expression	profiles	of	PTEN	and	PHLPP	
phosphatases.	Expression	of	PTEN	and	PHLPP	mRNA	(A	and	D,	respectively)	
and	protein	(B	and	E,	respectively),	relative	to	P7	WT	is	presented.	The	ratio	
of	phospho-PTEN	(T380/S382/S383)	to	total	PTEN	relative	to	the	ratio	in	P7	
WT	samples	is	presented	(C).	Representative	western	blots	shown	below	the	
respective	quantification.	Data	for	each	group	represented	as	the	mean	±	SEM	
for	three	animals.	*	p-value	<	0.05	(unpaired	student’s	t-test).		
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(P7)	and	gradually	decreased	throughout	development,	again	with	no	difference	
between	WT	and	Akt-DD	mice	(Figure	2-3B).	PTEN	activity	and	stability	are	also	
regulated	by	post-translational	modifications	of	its	C-terminal	tail,	where	
phosphorylation	increases	PTEN	stability	but	renders	the	protein	less	active	
(Vazquez	et	al.,	2000).	When	we	examined	levels	of	phospho-PTEN	
(S380/T382/T383)	in	these	samples,	we	observed	a	relatively	constant	ratio	of	
phospho-PTEN	to	total	PTEN	from	P10	through	P120,	and	that	ratio	did	not	differ	
between	wild	type	and	Akt-DD	mice	(Figure	2-3C).	Collectively,	there	are	no	
differences	between	wild	type	and	Akt-DD	mice	in	PTEN	mRNA	or	protein	
expression	or	in	the	ratio	of	phospho-PTEN/PTEN,	and	the	expression	profiles	
observed	did	not	meet	our	expectations	of	a	bonafide	“myelin	brake”	in	the	CNS.	
Although	the	conditional	knockout	studies	presented	above	suggest	that	PTEN	may	
play	a	role	in	curbing	active	myelination	(Goebbels	et	al.,	2010;	Harrington	et	al.,	
2010),	the	developmental	studies	presented	here	suggested	that	some	other	
molecule(s)	may	also	have	an	important	role	in	curbing	active	myelin	production	in	
the	CNS.	
We	therefore	extended	our	developmental	expression	profiling	studies	to	
other	putative	regulators	of	Akt	signaling	(Figure	2-1).	PHLPP	(Plekstrin	Homology	
domain	Leucine-rich	repeat	Protein	Phosphatase)	is	a	protein	phosphatase	that	
dephosphorylates	and	inactivates	Akt	directly	(Gao	et	al.,	2005),	and	forms	a	tumor	
suppressor	network	with	PTEN	and	the	scaffolding	protein	Nherf	that	is	disabled	in	
glioblastoma	(Molina	et	al.,	2011).	The	role	of	PHLPP	has	not	been	previously	
studied	in	myelinating	glia;	however,	PHLPP	has	been	shown	to	regulate	Akt	
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signaling	in	a	feedback	mechanism	mediated	by	mTOR	(Liu	et	al.,	2011a).	The	
expression	profile	of	PHLPP	mRNA	in	WT	mice	peaked	at	the	end	of	active	
myelination	(P30),	while	protein	levels	peaked	earlier,	at	P14.	PHLPP	mRNA	and	
protein	then	decreased	to	steady-state	levels	during	later	developmental	time	
points	(Figure	2-3D,E).	The	expression	of	PHLPP	mRNA	increased	throughout	the	
time	points	examined	in	Akt-DD	mice,	and	it	was	more	than	2-fold	increased	relative	
to	WT	at	P90	(Figure	2-3D);	however,	the	protein	expression	was	not	different	
between	WT	and	Akt-DD	mice	(Figure	2-3E).	These	results	suggested	differential	
regulation	of	PHLPP	mRNA	and	protein	during	the	development	of	the	corpus	
callosum,	where	levels	of	PHLPP	mRNA	were	increased	by	constitutively	active	Akt	
signaling	but	protein	levels	were	not.		
	
Developmental	expression	profiles	of	Ship-1	and	Ship-2	phosphatases.	Ship-1	
and	Ship-2	are	upstream	lipid	phosphatases	that	inhibit	the	formation	of	lipid	
second	messengers	that	activate	Akt	signaling	(Rauh	et	al.,	2004;	Dyson	et	al.,	2005).	
Figure	2-4.	Developmental	expression	profiles	of	Ship-1	and	Ship-2	
phosphatases.	Expression	of	Ship-1	and	Ship-2	mRNA	(A	and	B,	
respectively),	relative	to	P7	WT.	Data	represented	as	the	mean	±	SEM	for	
three	animals	per	group.	*	p-value	<	0.05	(unpaired	student’s	t-test).		
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In	WT	mice,	Ship-1	mRNA	levels	remained	constant	throughout	development.	
mRNA	levels	in	Akt-DD	mice	matched	WT	levels	at	early	time	points,	and	then	
increased	dramatically	at	later	time	points	(P60	and	P90)	(Figure	2-4A).	Ship-1	
protein	could	not	be	detected	via	western	blot	analysis,	most	likely	because	of	very	
low	expression	levels	in	the	tissue.	Ship-2	mRNA	in	WT	mice	slowly	increased	
during	early	development	and	peaked	at	P30,	corresponding	to	the	end	of	active	
myelination;	mRNA	levels	then	dropped	back	down	to	baseline	levels	at	later	time	
points.	In	Akt-DD	mice,	Ship-2	mRNA	peaked	sooner	at	P21,	remained	elevated	at	
Figure	2-5.	Developmental	expression	profiles	of	Shp1	and	Shp2	
phosphatases.	Expression	of	Shp1	and	Shp2	mRNA	(A	and	C,	respectively)	
and	protein	(B	and	D,	respectively),	relative	to	P7	WT.	Representative	
western	blots	shown	below	the	respective	quantification.	Data	for	each	group	
represented	as	the	mean	±	SEM	for	three	animals.	*	p-value	<	0.05	(unpaired	
student’s	t-test).		
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P30,	and	then	similarly	dropped	back	down	to	baseline	levels	at	later	time	points	
(Figure	2-4B).	As	with	Ship-1,	Ship-2	protein	expression	was	too	low	to	be	detected.		
	
Developmental	expression	profiles	of	Shp1	and	Shp2	phosphatases.	Shp1	
(PTPN6)	and	Shp2	(PTPN11)	are	nonreceptor	type	protein	tyrosine	phosphatases	
originally	described	for	their	ability	to	regulate	MAPK/ERK	signaling	but	have	since	
been	shown	to	regulate	multiple	intracellular	signaling	networks	(Navis	et	al.,	
2010).	Shp1	is	expressed	predominantly	in	hematopoietic	cells	(Green	and	Shultz,	
1975);	however,	mice	homozygous	for	the	motheaten	loss-of-function	mutation	in	
Shp1	display	a	variety	of	defects,	including	hypomyelination,	dysmyelination,	and	
decreased	numbers	of	differentiated	oligodendrocytes	in	the	brain	(Wishcamper	et	
al.,	2001;	Massa	et	al.,	2004).	WT	oligodendrocytes	have	been	shown	to	express	
functional	Shp1,	regulating	oligodendrocyte	differentiation	in	response	to	cytokine	
signaling	(Massa	et	al.,	2000).	In	our	analysis,	Shp1	mRNA	levels	peaked	at	P14	in	
WT	mice,	and	then	slowly	decreased	during	later	developmental	time	points.	In	Akt-
DD	mice,	a	gradual	increase	in	Shp1	mRNA	was	observed,	with	very	high	levels	at	
P90	that	differed	significantly	from	WT	(Figure	2-5A).	In	both	WT	and	Akt-DD,	Shp1	
protein	expression	increased	slowly,	peaked	at	P30,	and	remained	high	during	
adulthood	(Figure	2-5B).		
We	examined	developmental	expression	profiles	of	Shp2	mRNA	and	protein	
in	order	to	assess	its	function	during	development	due	to	its	role	in	regulating	Akt	
signaling	indirectly	(Marin	et	al.,	2011;	Nagata	et	al.,	2012)	and	its	known	role	in	
early	oligodendrocyte	development	(Zhu	et	al.,	2010;	Ehrman	et	al.,	2014).	In	WT	
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mice,	Shp2	mRNA	peaked	at	P30,	corresponding	to	the	end	of	active	myelination,	
and	then	decreased	to	steady-state	levels	during	later	time	points	(Figure	2-5C).	The	
same	expression	pattern	was	observed	with	Shp2	protein	(Figure	2-5D).	In	Akt-DD	
mice,	both	Shp2	mRNA	and	protein	increased	gradually	throughout	the	time	points	
examined,	with	significant	differences	between	WT	and	Akt-DD	at	the	mRNA	level	at	
P90	and	significant	differences	between	WT	and	Akt-DD	at	the	protein	level	at	P60	
and	P120	(Figure	4C,D).	Like	PTEN,	Shp2	activity	is	also	regulated	by	post-
translational	modifications,	where	phosphorylation	of	two	carboxy-terminal	
tyrosine	residues	relieves	basal	inhibition	of	the	phosphatase	domain	(Lu	et	al.,	
2001);	however,	we	were	unable	to	detect	phospho-Shp2	in	our	experimental	
conditions	(data	not	shown).	Nevertheless,	the	expression	profile	of	Shp2	transcript	
and	protein	in	wild	type	and	Akt-DD	mice	suggest	strongly	that	this	protein	may	
play	a	role	in	regulating	Akt/mTOR	signaling	driving	myelination	as	a	potential	
myelin	brake	in	the	CNS.		
	
Discussion	
	
Collectively,	the	data	presented	here	demonstrate	that	molecules	other	than	
PTEN	deserve	consideration	as	potential	‘myelin	brake’	candidates	in	the	CNS.	PTEN	
seems	to	fulfill	the	role	of	the	‘myelin	brake’	in	the	PNS,	however,	many	fundamental	
differences	between	PNS	and	CNS	myelination	exist,	only	some	of	which	have	been	
highlighted	here.	In	addition	to	PTEN,	other	mechanisms	may	exist	to	regulate	the	
hypothesized	master	regulatory	function	of	Akt/mTOR	signaling	on	CNS	
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myelination.	It	is	likely	that	cross-talk	between	Akt/mTOR	and	other	signaling	
pathways,	notably	MAPK/ERK	(Dai	et	al.,	2014),	exist	in	order	to	provide	intricate	
regulation	over	this	highly	advanced	and	delicate	system.		
Although	PHLPP	mRNA	met	our	criteria	for	a	putative	myelin	brake,	PHLPP	
protein	did	not.	These	results	suggested	a	differential	regulation	of	PHLPP	at	the	
transcriptional	and	translational	levels	and/or	differential	stability	of	PHLPP	mRNA	
compared	to	PHLPP	protein.	Since	PHLPP	protein	inhibits	Akt	activity,	differences	in	
protein	levels	are	more	relevant	for	our	studies	than	mRNA	levels,	and	we	have	
focused	less	on	PHLPP	as	a	likely	myelin	brake	candidate.	Similarly,	given	the	
interesting	differences	in	RNA	expression	levels	of	Ship-1	and	Ship-2,	these	
phosphatases	have	potential	to	regulate	aspects	of	Akt	signaling	in	
oligodendrocytes.	However,	because	of	the	difficulty	in	detecting	these	proteins,	
pursuing	Ship-1/2	as	myelin	brake	candidates	may	be	difficult.		
The	expression	profile	for	Shp1	protein	suggested	it	could	be	involved	as	a	
myelin	brake,	as	expression	peaked	at	P30	and	remained	elevated	during	later	
developmental	stages.	Furthermore,	Shp1	transcripts	were	markedly	elevated	in	
Akt-DD	mice.	However,	previous	studies	seem	to	suggest	that	Shp1	mutant	mice	
have	impaired	myelin	formation,	rather	than	enhanced	(Massa	et	al.,	2000).	
Finally,	Shp2	is	a	protein	tyrosine	phosphatase	that	is	traditionally	
considered	a	positive	regulator	ERK	signaling	(Navis	et	al.,	2010);	however,	Shp2	is	
now	known	to	also	to	negatively	regulate	Akt/mTOR	signaling	in	some	cellular	
contexts	(Marin	et	al.,	2011;	Nagata	et	al.,	2012).	Furthermore,	Shp2	has	known	
functions	in	oligodendrocyte	generation	and	proliferation	in	vivo	(Zhu	et	al.,	2010;	
33	
Ehrman	et	al.,	2014).	The	expression	profile	of	Shp2	in	WT	and	Akt-DD	mice	
strongly	implicate	this	protein	as	a	potential	negative	regulator	of	myelination.	
Furthermore,	its	ability	to	regulate	multiple	signaling	pathways	make	it	an	
attractive	regulator	of	CNS	myelination	specifically,	due	to	the	inherently	complex	
nature	of	CNS	myelin	formation.	
Myelin	overproduction	is	observed	in	the	PNS	in	diseases	such	as	Charcot-
Marie-Tooth	disease	(Bolino	et	al.,	2000;	Massa	et	al.,	2006)	and	the	hereditary	
neuropathy	with	liability	to	pressure	palsies	(HNLPP)	(Adlkofer	et	al.,	1997).	
Genetic	analyses	have	helped	to	pinpoint	specific	genes	responsible	for	the	
disruptions	and	further	our	understanding	of	myelination	(Cotter	et	al.,	2010;	
Goebbels	et	al.,	2012).	An	obstacle	impeding	progress	in	understanding	myelination	
in	the	CNS	is	the	fact	that	hypermyelination	is	rarely	observed	in	human	disease,	
and	the	molecules	involved	in	PNS	myelination	are	not	always	conserved	in	CNS	
myelination	(Brinkmann	et	al.,	2008).	The	hypermyelinating	phenotype	observed	in	
the	CNS	as	a	result	of	constitutively	active	Akt	signaling	in	oligodendrocytes	(Flores	
et	al.,	2008)	represents	a	significant	advancement	on	this	front	and	will	serve	as	a	
useful	tool	in	elucidating	more	precise	mechanisms	of	regulatory	control	over	CNS	
myelination.	
A	key	to	understanding	CNS	myelination	is	to	identify	cell-autonomous	
changes	within	myelinating	oligodendrocytes	as	the	cell	progresses	from	initiation	
of	myelination	to	active	myelin	accumulation	and	then	to	myelin	maintenance.	
Differentiation	of	oligodendrocytes	does	not	imply	myelination	per	se,	and	the	
developmental	program	of	oligodendrocytes	appears	to	be	more	complex	than	
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traditionally	viewed.	Achieving	a	thorough	understanding	of	the	molecular	
mechanisms	responsible	for	the	regulation	of	CNS	myelination	will	undoubtedly	
improve	our	knowledge	about	human	myelin	disorders	and	pathology.	This	
heightened	understanding	will	elucidate	novel	therapeutic	approaches	that	will	
enable	more	effective	treatments.		
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CHAPTER	III	
THE	PROTEIN	TYROSINE	PHOSPHATASE	SHP2	REGULATES	
OLIGODENDROCYTE	DIFFERENTIATION	AND	EARLY	MYELIN	FORMATION	
DURING	DEVELOPMENT	AND	REMYELINATION	
	
Summary	
	
Shp2	is	a	nonreceptor	protein	tyrosine	phosphatase	that	has	been	shown	to	
influence	neurogenesis,	oligodendrogenesis,	and	oligodendrocyte	differentiation.	
Furthermore,	Shp2	is	a	known	regulator	of	the	Akt/mTOR	and	ERK	signaling	
pathways	in	multiple	cellular	contexts,	including	oligodendrocytes.	Its	role	during	
later	postnatal	CNS	development	or	in	response	to	demyelination	injury	has	not	
been	examined.	Based	on	these	data,	and	data	presented	above,	we	hypothesize	that	
Shp2	is	a	negative	regulator	of	CNS	myelination.	Using	transgenic	mouse	technology,	
we	show	that	Shp2	promotes	oligodendrocyte	differentiation	and	early	myelination,	
but	is	not	necessary	for	myelin	maintenance.	Interestingly,	although	fewer	axons	
were	myelinated	in	conditional	knockout	mice	compared	to	wild	type	controls,	
thicker	myelin	was	observed	on	myelinated	axons.	This	increase	in	myelin	thickness	
coincided	with	increased	focal	adhesion	kinase	activation,	but	not	Akt/mTOR	or	
ERK	signaling.	We	also	show	that	Shp2	regulates	the	timely	differentiation	of	
oligodendrocytes	following	lysolecithin-induced	demyelination.	These	data	suggest	
that	Shp2	is	a	relevant	therapeutic	target	in	demyelinating	diseases	such	as	multiple	
sclerosis.	
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Introduction	
	
The	coordinated	production	of	myelin	is	required	for	proper	development	
and	function	of	the	nervous	system.	However,	the	molecular	mechanisms	directing	
these	events	in	vivo	are	not	well	understood.	The	PI3K/Akt/mTOR	signaling	
pathway	is	important	for	driving	active	myelination	in	the	central	nervous	system	
(CNS).	The	overexpression	of	constitutively	active	Akt	within	oligodendrocytes	
results	in	CNS	hypermyelination	and	can	be	rescued	by	treatment	with	the	mTOR	
inhibitor	rapamycin	(Flores	et	al.,	2008;	Narayanan	et	al.,	2009).	The	signaling	
mechanisms	that	downregulate	Akt	signaling	in	oligodendrocytes	after	the	
appropriate	amount	of	myelin	has	been	formed	remain	unknown.	
In	order	to	identify	the	“myelin	brake”	of	the	CNS,	we	previously	screened	
multiple	negative	regulators	of	the	Akt	signaling	for	developmental	expression	
profiles	suggestive	of	a	role	in	downregulating	the	myelination	process.	The	protein	
tyrosine	phosphatase	Shp2	was	identified	as	a	putative	negative	regulator	of	
myelination	(Ahrendsen	and	Macklin,	2013).	Shp2,	also	known	as	PTPN11,	is	
traditionally	considered	a	positive	regulator	ERK	signaling	(Navis	et	al.,	2010);	
however,	Shp2	is	now	known	to	also	to	negatively	regulate	Akt/mTOR	signaling	in	
some	cellular	contexts,	including	oligodendrocytes	(Marin	et	al.,	2011;	Liu	et	al.,	
2011b;	Nagata	et	al.,	2012).	
Shp2	influences	neural	and	glial	specification	during	early	nervous	system	
development	(Coskun	et	al.,	2007;	Grossmann	et	al.,	2009).	In	particular,	Shp2	
expression	by	oligodendrocytes	influences	in	vitro	differentiation	of	primary	
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oligodendrocytes	via	Akt	and	ERK1/2	signaling	(Liu	et	al.,	2011b).	Shp2	activity	
maintains	cultured	OPCs	in	a	state	of	proliferation	and	opposes	the	pro-
differentiation	effects	of	Shp1	(Kuo	et	al.,	2010).	Likewise,	Shp2	conditional	
knockout	decreases	OPC	proliferation	and	generation	in	vivo,	but	its	effects	during	
later	stages	of	oligodendrocyte	differentiation	and	myelination	could	not	be	
analyzed	due	to	early	postnatal	lethality	of	experimental	animals	(Zhu	et	al.,	2010;	
Ehrman	et	al.,	2014).	Interestingly,	the	transgenic	expression	of	a	Shp2	gain	of	
function	mutation	in	oligodendrocytes	results	in	elevated	numbers	of	
oligodendrocytes	precursor	cells	(OPCs),	fewer	myelinated	axons,	and	abnormal	
myelination	in	the	forebrain	(Ehrman	et	al.,	2014).		
Together,	these	results	suggest	that	oligodendrocyte	Shp2	has	stage	specific	
effects,	influencing	OPC	proliferation,	oligodendrocyte	differentiation,	and	
myelination.	However,	the	role	of	Shp2	during	myelination	specifically	has	not	been	
characterized	due	to	early	post-natal	lethality	of	transgenic	animals.	Furthermore,	
the	role	of	Shp2	during	remyelination	has	not	been	examined.	We	hypothesize	that	
Shp2	is	a	negative	regulator	of	myelination	and	remyelination	by	downregulating	
Akt/mTOR	signaling.	Using	conditional	and	inducible	transgenic	mouse	
technologies,	we	show	here	that	oligodendrocyte	Shp2	influences	oligodendrocyte	
differentiation	and	early	stages	of	myelination.	The	effects	of	Shp2	on	early	
myelination	seem	to	be	due	to	elevated	focal	adhesion	kinase	(FAK)	signaling,	rather	
than	Akt/mTOR.	However,	oligodendrocyte	Shp2	is	not	necessary	for	long-term	
maintenance	of	CNS	myelin.	Furthermore,	we	show	that	Shp2	is	necessary	for	timely	
oligodendrocyte	differentiation	following	lysolecithin-induced	demyelination.	These	
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studies	demonstrate	that	Shp2	influence	the	early	stages	of	myelination	and	could	
function	as	part	of	the	braking	mechanism	of	CNS	myelination.	Furthermore,	its	role	
in	oligodendrocyte	differentiation	during	remyelination	makes	Shp2	an	attractive	
therapeutic	target	for	demyelinating	disorders,	such	as	multiple	sclerosis.	
	
Experimental	procedures	
	
Animals.	All	experimental	protocols	were	approved	by	the	Institutional	
Animal	Care	and	Use	Committee	at	the	University	of	Colorado	School	of	Medicine,	
and	conformed	to	the	National	Institutes	of	Health	guidelines	for	the	care	and	use	of	
animals	in	research.	For	Cre-mediated	recombination	of	Shp2	in	oligodendrocyte	
lineage	cells,	mice	of	either	sex	carrying	the	floxed	allele	of	Shp2	(Shp2fl/fl;	Mutant	
Mouse	Regional	Resource	Center	(Zhang	et	al.,	2004))	were	bred	to	CNPcre/+	mice	
(Lappe-Siefke	et	al.,	2003),	to	generate	the	following	genotypes:	CNPcre/+;Shp2fl/fl	
(experimental	animals,	cKO),	CNP+/+;Shp2fl/fl	and	CNPcre/+;Shp2fl/+	(wild	type	
controls,	WT).	For	Cre-mediated,	tamoxifen	inducible	recombination	of	Shp2	in	
oligodendrocyte	lineage	cells,	Shp2fl/fl	mice	were	bred	to	PLPcreERT/+	mice	
(Doerflinger	et	al.,	2003),	to	generate	PLPcreERT/+;Shp2fl/fl	and	PLP+/+;Shp2fl/fl	
animals.	All	animals	were	maintained	on	a	C57Bl/6	background.	
	
Tamoxifen	administration.	Tamoxifen	(Sigma-Aldrich)	was	dissolved	in	
sunflower	oil/ethanol	(10:1)	to	a	final	concentration	of	10	mg/ml.	For	
developmental	studies,	mice	received	intraperitoneal	(i.p.)	injections	at	100	μg	of	
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tamoxifen	per	gram	of	mouse	weight	once	a	day	for	10	consecutive	days,	starting	at	
either	post	natal	day	25	(P25)	or	P85.	As	vehicle	control,	sunflower	oil/ethanol	
(10:1)	was	injected.	For	lysolecithin	studies,	mice	received	the	same	dosing	for	7	
consecutive	days	starting	3	days	after	the	lysolecithin	procedure.		
	
Lysolecithin	induced	demyelination.	Lysolecithin	surgeries	were	performed	by	
Danielle	Harlow	in	Wendy	Macklin’s	lab	at	the	University	of	Colorado	Anschutz	
Medical	Campus.	PLPcreERT/+;Shp2fl/fl	and	PLP+/+;Shp2fl/fl	littermates	8-12	weeks	old	
were	used	for	lysolecithin	induced	demyelination	studies.	Anesthesia	was	induced	
with	i.p.	injection	of	Ketamine/Xylazine.	Dorsal	laminectomy	was	performed	at	the	
T10-11	level,	a	Hamilton	needle	was	advanced	lateral	to	the	central	vein,	and	1.0	μl	
of	1%	lysolecithin	(L-α-lysophosphatidylcholine,	Sigma)	in	saline	was	injected	into	
the	dorsal	white	matter.	Animals	were	monitored	closely	following	surgery	and	
were	sacrificed	for	analyses	at	14,	21,	and	35	days	post-lesion	(dpl).	
	
Immunohistochemistry	(IHC).	Mice	were	briefly	anesthetized	with	isoflurane	
and	tissue	was	fixed	by	transcardial	perfusion	with	PBS	followed	by	4%	
paraformaldehyde.	Brains	and	spinal	cords	were	dissected,	postfixed	overnight,	and	
transferred	to	cryoprotection	solution	(20%	glycerol	in	0.1	M	Sorenson’s	buffer,	pH	
7.6).	The	immunohistochemistry	protocol	was	adapted	from	previously	described	
studies	(Trapp	et	al.,	1997).	Tissues	were	sectioned	at	30	μm	on	a	sliding	microtome	
and	sections	were	stored	at	4°C	in	cryostorage	solution	(30%	ethylene	glycol,	30%	
sucrose,	and	1%	PVP-40	in	0.1	M	Sorenson’s	buffer).	Free-floating	sections	were	
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washed	in	PBS	and	antigen	retrieval	was	performed	with	10	mM	sodium	citrate	(pH	
6.0)	+	0.05%	Tween-20	for	10	minutes	at	550	W	in	a	PELCO	BioWave	Pro	tissue	
processor	(Ted	Pella).	Sections	were	then	washed	in	PBS,	permeabilized	with	0.3%-
10%	Triton	X-100	(dependent	on	specific	antibodies),	blocked	with	5%	normal	
donkey	serum,	and	incubated	with	primary	antibody	for	1-3	days	at	4°C.	The	
following	primary	antibodies	were	used:	rabbit	anti-Shp2	(Cell	Signaling);	mouse	
anti-CC1	(Calbiochem);	rabbit	anti-MOG	(Abcam);	mouse	anti-SMI94	(MBP,	
Covance);	rabbit	anti-Olig2	(a	gift	from	Dr.	Charles	Stiles,	Harvard	University);	rat	
anti-PDGFRα	(BD	Biosciences).	For	fluorescent	IHC,	sections	were	incubated	with	
the	appropriate	Alexa-fluor	conjugated	secondary	antibodies	(Jackson	
ImmunoResearch)	for	2	hours	at	room	temperature	and	mounted	on	glass	slides	in	
Vectashield	Mounting	Media	(Vector	Laboratories).	For	DAB	(3,3’-
diaminobenzidine)	IHC,	sections	were	incubated	with	the	appropriate	biotinylated	
conjugated	secondary	antibodies	(Jackson	ImmunoResearch),	followed	by	
incubation	with	avidin-biotin	complex	(ABC	reagent,	Vector	Laboratories).	Sections	
were	washed	and	incubated	in	diaminobenzidine	(DAB	kit,	Vector	Laboratories)	and	
the	myelin	staining	was	amplified	by	brief	exposure	to	0.08%	osmium	tetroxide.	
Sections	were	transferred	to	60%	glycerol	before	mounting	on	glass	slides	in	100%	
glycerol.	Images	for	fluorescent	IHC	were	acquired	using	a	Leica	TCS	SP5	II	confocal	
microscope	using	identical	imaging	parameters	for	ipsilateral	and	contralateral	
images.	Images	for	DAB	IHC	were	acquired	with	a	Leica	DMR	microscope	and	
DFC290HD	digital	camera	using	Leica	Application	Suite	(LAS)	software	(Leica	
Microsystems).		
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Cell	Counting.	For	developmental	studies,	cells	were	quantified	from	images	
acquired	in	the	primary	motor	cortex.	At	least	4	images	were	taken	from	each	
hemisphere	per	stained	section,	and	at	least	two	sections	were	stained	per	animal.	
Four	animals	per	group	were	analyzed.	Oligodendrocytes	were	quantified	by	
expression	of	Olig2.	Oligodendrocyte	precursor	cells	were	identified	by	co-
expression	of	PDGFRα	and	Olig2.	Mature	oligodendrocytes	were	identified	by	co-
expression	of	CC1	and	Olig2.	For	demyelination	studies,	images	were	taken	at	the	
lesion	core	in	the	dorsal	white	matter	tracts.	At	least	two	sections	were	analyzed	per	
animal.	The	Cell	Counter	plug-in	on	Fiji	software	(Schindelin	et	al.,	2012)	was	used	
for	all	cell	count	analyses.		
	
Western	blot.	Tissue	isolated	from	the	oligodendrocyte-enriched	corpus	
callosum	was	snap	frozen	in	liquid	nitrogen	and	stored	at	-80°C	until	lysis.	Tissue	
was	lysed	in	glass	homogenizers	in	radioimmunoprecipitation	assay	buffer	(RIPA,	
Sigma)	supplemented	with	phosphatase	inhibitor	cocktail	(Calbiochem)	and	
protease	inhibitor	(Complete-mini;	Roche).	The	lysates	were	centrifuged	at	for	10	
min	at	4°C	and	the	supernatants	were	collected	for	protein	quantification	using	a	
BCA	Protein	Assay	Kit	(Thermo	Fisher).	The	lysates	were	subjected	to	SDS-PAGE	(4-
20%	gradient	gel;	BIO-RAD)	and	the	proteins	transferred	to	PVDF	membranes.	The	
membranes	were	blocked	with	5%	bovine	serum	albumin	in	TBS	and	then	
incubated	with	the	following	antibodies	overnight	at	4°C	(all	from	Cell	Signaling	
unless	otherwise	noted):	rabbit	anti-Shp2;	rabbit	anti-phospho	Akt	S473;	mouse	
anti-pan	Akt;	rabbit	anti-phospho	mTOR	S2448;	mouse	anti-pan	mTOR;	rabbit	anti-
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phospho	ERK1/2;	mouse	anti-pan	ERK;	rabbit	anti-phospho-FAK	Y397;	rabbit	anti-
pan	FAK;	rabbit	anti-GAPDH;	rabbit	anti-MAG	(Abcam);	mouse	anti-SMI94	(MBP,	
Covance);	rat	anti-PLP/DM20	(Clone	AA3,	(Yamamura	et	al.,	1991)).	Blots	were	
scanned	and	quantified	using	an	Odyssey	infrared	imager	(LI-COR).	
	
Electron	microscopy.	For	electron	microscopy,	animals	were	perfused	with	
modified	Karnovsky’s	fixative	(2%	paraformaldehyde/	2.5%	glutaraldehyde)	in	
phosphate	buffer,	pH	7.4.	The	brain	was	removed	and	immersed	in	the	same	fixative	
overnight.	Corpus	callosum	was	isolated	from	1	mm	coronal	slices	of	brain	between	
-0.94	and	-2.18	of	bregma	(Franklin	and	Paxinos,	2008).	Using	a	PELCO	Biowave	Pro	
tissue	processor	(Ted	Pella),	the	tissue	was	rinsed	in	100	mM	cacodylate	buffer	and	
then	post-fixed	in	a	reduced	osmium	mixture	consisting	of	1%	osmium	tetroxide	
and	1.5%	potassium	ferrocyanide	followed	by	1%	osmium	tetroxide	alone.	
Dehydration	was	carried	out	in	a	graded	series	of	acetone	(50%,	70%,	90%,	100%)	
containing	2%	uranyl	acetate	for	en	bloc	staining.	Finally,	tissue	was	infiltrated	and	
embedded	in	Embed	812	(Electron	Microscopy	Services)	and	cured	for	48	hr	at	60°C	
in	an	oven.	The	corpus	callosum	pieces	were	oriented	such	that	sections	could	be	
cut	midline	in	a	sagittal	plane.	Ultrathin	sections	(65	nm)	were	mounted	on	copper	
mesh	grids	and	viewed	at	80	kV	on	a	Tecnai	G2	transmission	electron	microscope	
(FEI).	Electron	micrographs	of	the	corpus	callosum	were	imaged	near	the	midline.	
	
G-ratio	analysis.	G-ratios	of	myelinated	fibers	were	calculated	as	the	ratio	of	
the	diameter	of	the	axon	to	the	diameter	of	the	myelinated	fiber.	Diameters	were	
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derived	by	measuring	the	respective	perimeters	using	FIJI	software.	A	minimum	of	
100	axons	per	condition	were	quantified,	and	samples	were	analyzed	from	four	
animals	per	experimental	group.		
	
Statistical	analysis.	Unpaired,	two-tailed	Student’s	t-test	was	used	to	calculate	
statistical	significance	between	cKO	and	WT	groups.	One-way	ANOVA	with	multiple	
comparisons	was	used	to	determine	statistical	significance	between	icKO	and	
control	groups	in	tamoxifen	experiments.	A	p-value	of	less	than	0.05	was	designated	
as	statistically	significant.	Graphs	represent	the	mean	±	SEM.	Graphs	were	created	
and	statistics	were	performed	using	Prism	6	software	(www.graphpad.com).	
Figure	3-1.	Conditional	knockout	of	Shp2	from	oligodendrocytes.	(A)	cKO	
animals	are	smaller	than	WT	control	animals.	Immunohistochemical	
demonstration	that	Shp2	(green)	is	present	in	WT	oligodendrocytes	(Sox10-
positive	cells,	red)	(B)	but	not	in	cKO	oligodendrocytes	(C).	Quantification	of	
Shp2	colocalization	with	Sox10	in	WT	(open	bar)	and	cKO	(dark	bar)	(D).	
White	scale	bars:	25	μm.	*p-value	<	0.05.	
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Results	
	
Shp2	conditional	knockout	with	CNP	driven	cre-recombination.	Previous	in	
vivo	studies	examining	the	role	of	Shp2	in	oligodendrocytes	were	limited	by	early	
post-natal	lethality.	Shp2	conditional	knockout	mice	failed	to	survive	past	postnatal	
day	21	(P21)	using	either	the	Olig1-cre	or	Olig2-cre	transgenic	mice,	therefore	
preventing	a	detailed	characterization	of	later	postnatal	development	(Zhu	et	al.,	
2010;	Ehrman	et	al.,	2014).	In	an	attempt	to	extend	the	survival	of	Shp2	conditional	
knockout	mice,	we	utilized	the	CNP-cre	transgenic	mouse,	in	which	recombination	
occurs	later	during	embryonic	development	(Genoud	et	al.,	2002;	Lappe-Siefke	et	al.,	
2003;	Furusho	et	al.,	2006).	The	Shp2	conditional	knockouts	generated	
(CNPcre/+;Shp2fl/fl,	herein	referred	to	as	cKO)	were	smaller	than	wild	type	litter	
mates	(CNPcre/+;Shp2fl/+	and	CNP+/+;Shp2fl/fl,	herein	referred	to	as	WT)	(Figure	3-1A)	
and	developed	significant	shaking	and	unbalanced	movements	starting	at	P10.	The	
shaking	phenotype	observed	is	typical	for	myelin	abnormalities	during	development	
(Molineaux	et	al.,	1986).	Survival	was	prolonged	in	these	cKO	animals	to	4	weeks	of	
age.	Animals	were	sacrificed	by	P28	for	ethical	reasons	due	to	severe	hind	limb	
paralysis	rendering	the	animals	unable	to	properly	feed	themselves.		
In	order	to	verify	the	efficiency	of	cre-mediated	recombination	of	the	floxed	
Shp2	alleles,	Shp2	immunostaining	was	performed	on	WT	and	cKO	brain	tissue	
(Figure	3-1B,	C).	Shp2	immunostaining	was	detectable	in	83.4%	of	Sox10-positive	
cells	in	the	corpus	callosum	of	WT	animals	and	in	only	7.3%	of	Sox10-positive	cells	
in	the	corpus	callosum	of	cKO	animals	(Figure	3-1D).	Thus,	recombination	efficiency	
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was	greater	than	90%.	We	also	observed	significantly	less	Shp2	protein	by	western	
blot	in	corpus	callosum	samples	from	WT	and	cKO	animals	at	P14	and	P28	(Figure	
3-3A).	Thus,	the	Shp2	gene	was	effectively	recombined	from	oligodendrocyte	
lineage	cells.	
	
Figure	3-2.	Delayed	oligodendrocyte	differentiation	in	the	Shp2	cKO	
brain.	WT	(A-C)	and	cKO	(D-F)	sections	were	immunostained	to	detect	OPCs	
(PDGFRα	,	green),	total	oligodendrocytes	(Olig2,	red),	and	mature	
oligodendrocytes	(CC1,	blue)	at	P14,	P21	and	P28.	(G)	Quantification	of	
oligodendrocytes	in	WT	(open	bar)	versus	cKO	(dark	bar)	cortex.	(H)	
Quantification	of	OPCs,	identified	by	double	staining	with	PDGFRα	and	Olig2.	
(I)	Quantification	of	mature	oligodendrocytes,	identified	by	double	staining	
with	CC1	and	Olig2.	White	scale	bars:	100	μm.	*p-value	<	0.05.	
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Figure	3-3.	Abnormal	myelination	in	the	Shp2	cKO	brain.	
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Delayed	oligodendrocyte	differentiation	in	the	Shp2	cKO	brain.	In	order	to	
assess	the	effect	of	Shp2	cKO	on	oligodendrocyte	generation	and	differentiation,	we	
utilized	a	panel	of	histological	markers.	Olig2	is	a	transcription	marker	expressed	by	
all	cells	in	the	oligodendrocyte	lineage;	PDGFRα	is	a	receptor	expressed	by	OPCs;	
and	CC1	is	a	marker	for	differentiated	oligodendrocytes.	At	P14,	there	were	30%	
fewer	Olig2-positive	cells	in	the	cortex	of	Shp2	cKO	animals	compared	to	WT	
controls	(Figure	3-2A,	D,	G).	Similarly,	at	P21,	we	observed	20%	fewer	Olig2-
positive	cells	in	cKO	animals	compared	to	WT	(Figure	3-2B,	E,	G).	By	28,	the	number	
of	Olig2-positive	cells	was	not	different	in	cKO	animals	compared	to	WT	(Figure	3-
2C,	F,	G).	These	data	suggest	that	there	are	fewer	oligodendrocyte	lineage	cells	in	the	
cortex	of	Shp2	cKO	animals	during	the	first	3	weeks	of	postnatal	development	that	
gradually	catches	up	to	WT	levels	by	the	4	weeks	of	age.	
	 Because	Olig2	does	not	discriminate	between	OPCs	and	mature	
oligodendrocytes,	we	quantified	the	numbers	of	PDGFRα/Olig2-double	positive	
OPCs	and	CC1/Olig2-double	positive	mature	oligodendrocytes.	The	number	of	
PDGFRα/Olig2-double	positive	cells	did	not	differ	between	cKO	and	WT	animals	at	
Figure	3-3.	Abnormal	myelination	in	the	Shp2	cKO	brain.	(A)	
Representative	western	blots	from	P14	(left)	and	P28	(right)	corpus	callosum	
lysates	of	WT	and	cKO	animals.	(B)	Representative	coronal	sections	of	the	
corpus	callosum	immunostained	with	MOG	from	P14	(left)	and	P28	(right)	
WT	and	cKO	animals.	Representative	electron	micrographs	from	WT	(C,	D)	
and	cKO	(E,	F)	animals	at	P14	and	P28.	(D’,	F’)	High	magnfication	images	of	
individual	myelinated	axons	in	WT	and	cKO	animals.	Scatter	plots	of	axon	
diameter	versus	g-ratio	for	individual	myelinated	axons	from	WT	(black	dots,	
solid	line)	and	cKO	(red	dots,	dashed	line)	at	P14	(G)	and	P28	(H).	
Quantification	of	average	density	of	myelinated	axons	(I)	and	average	g-ratio	
(J)	in	WT	and	cKO	corpus	callosum.	Scale	bars	in	B:	250	μm;	C-F:	1	μm;	D’,	F’:	
500	nm.	*p-value	<	0.05.	
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any	time	point	examined	(Figure	3-2A-F,	H).	However,	the	number	of	CC1/Olig2-
double	positive	mature	oligodendrocyte	was	significantly	decreased	at	P14	and	P21	
in	the	cortex	of	cKO	animals	compared	to	WT	(Figure	3-2I).	Again,	the	number	of	
mature	oligodendrocytes	in	the	Shp2	cKO	animals	returned	to	WT	levels	by	P28	
(Figure	3-2C,	F,	I).	Together,	these	data	suggest	that	the	decreased	number	of	
oligodendrocytes	in	the	cortex	of	Shp2	cKO	animals	is	due	to	a	delay	in	
differentiation,	and	not	a	defect	in	OPC	production.	
	
Abnormal	myelination	in	the	Shp2	cKO	brain.	We	next	examined	whether	the	
conditional	knockout	of	Shp2	from	oligodendrocytes	affected	myelination	in	the	
corpus	callosum.	Western	blots	at	P14	showed	decreased	levels	in	both	myelin	basic	
protein	(MBP)	and	proteolipid	protein	(PLP),	two	major	protein	components	of	the	
myelin	membrane	(Figure	3-3A).	Similarly,	immunohistochemical	staining	against	
myelin	oligodendrocyte	glycoprotein	(MOG)	showed	decreased	myelin	protein	in	
the	corpus	callosum	of	cKO	animals	compared	to	WT	(Figure	3-3B).	At	P28,	myelin	
protein	levels	were	not	different	between	cKO	and	WT	littermates,	as	assessed	by	
western	blot	and	immunohistochemistry	(Figure	3-3A,	B).		
	 In	order	to	determine	the	effect	of	Shp2	cKO	on	individual	myelinated	axons,	
we	assessed	cKO	and	WT	tissue	using	electron	microscopy.	At	P14	and	P28,	we	
observed	significantly	fewer	numbers	of	myelinated	axons	in	the	midline	corpus	
callosum	(Figure	3-3C-F,	I).	Furthermore,	at	P14	the	thickness	of	myelin	was	not	
different	in	cKO	corpus	callosum	compared	to	WT	(Figure	3-3C,	E,	G,	J).	
Interestingly,	at	P28,	while	fewer	axons	were	myelinated	in	cKO	animals,	the	
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thickness	of	myelin	on	average	was	significantly	greater	in	cKO	compared	to	WT	
(Figure	3-3D,	F,	H,	J).	The	decreased	g-ratios	observed	in	cKO	animals	at	P28	were	
consistent	across	all	sizes	of	axons	(Figure	3-3H).	These	results	suggest	that	Shp2	
myelination	is	delayed	in	the	cKO	brain	and	could	be	important	in	regulating	myelin	
sheath	thickness	during	active	myelin	production.		
	 Akt	signaling	through	mTOR	is	an	important	driver	of	CNS	myelination	
(Flores	et	al.,	2008;	Narayanan	et	al.,	2009)	and	Shp2	is	a	known	regulator	of	Akt	
signaling	in	cultured	oligodendrocytes	(Liu	et	al.,	2011b).	Therefore,	we	examined	
major	signaling	pathways	in	the	corpus	callosum	of	Shp2	cKO	and	WT	littermates.	
At	P14	and	P28,	we	observed	no	differences	in	the	levels	of	phospho-Akt	S473	or	
phospho-mTOR	S2448	between	WT	and	cKO	(Figure	3-4A-C).	The	ERK	and	focal	
adhesion	kinase	(FAK)	signaling	pathways	have	also	been	shown	to	be	important	in	
Figure	3-4.	FAK	signaling,	not	Akt/mTOR	or	ERK	signaling,	altered	in	
Shp2	cKO	corpus	callosum.	(A)	Representative	western	blots	and	
quantification	(B)	from	P14	(left)	and	P28	(right)	corpus	callosum	lysates	of	
WT	and	cKO	animals.	Quantification	performed	on	Odyessey	software	and	
phospho	signaling	was	evaluated	relative	to	total	protein.	For	each	signaling	
component,	cKO	values	are	displayed	as	a	percentage	of	WT	(set	to	100).	*p-
value	<	0.05.	
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regulating	CNS	myelination	(Forrest	et	al.,	2009;	Ishii	et	al.,	2012;	2013).	At	P14	and	
P28,	we	observed	no	difference	in	the	level	of	phospho-ERK	in	the	corpus	callosum	
between	WT	and	cKO	(Figure	3-4A-C).	Similarly,	no	differences	were	noted	in	the	
levels	of	phospho-FAK	signaling	between	cKO	and	WT	animals	at	P14	(Figure	3-4A,	
B).	However,	at	P28,	a	significant	increase	in	the	level	of	phospho-FAK	was	observed	
in	cKO	compared	to	WT	(197	±	22.5%,	relative	to	WT)	(Figure	3-4A,	C).	Thus,	the	
increased	myelination	in	the	P28	brains	of	cKO	animals	was	not	due	to	alterations	in	
Akt/mTOR	or	ERK	signaling,	but	did	coincide	with	increased	FAK	signaling.	
	 	
Oligodendrocyte	Shp2	is	not	necessary	for	long-term	maintenance	of	
myelination.	The	results	in	Figure	3-3	suggested	that	Shp2	could	be	involved	in	
regulating	myelin	production	in	actively	myelinating	oligodendrocytes.	To	address	
this	question	more	directly,	without	the	compounding	effects	of	Shp2	function	
during	early	oligodendrocyte	generation,	we	utilized	the	tamoxifen	inducible	form	
of	cre-recombinase	driven	in	oligodendrocyte	lineage	cells	by	the	PLP	promotor	
(PLP-creERT).	The	floxed	Shp2	alleles	were	crossed	into	the	PLP-creERT	line	to	
generate	PLPcreERT/+;Shp2fl/fl	(tamoxifen	treated	animals	referred	to	as	icKO,	vehicle	
treated	animals	referred	to	as	Veh	Con)	and	PLP+/+;Shp2fl/fl	(treated	with	tamoxifen	
and	referred	to	as	Tam	Con).	In	order	to	examine	the	role	of	Shp2	during	active	
myelination,	tamoxifen	or	vehicle	was	administered	once	per	day	for	10	days	
starting	at	P25	and	sacrificed	6	or	12	weeks	after	the	final	injection.	Animals	were	
analyzed	for	myelin	changes	by	western	blot	12	weeks	after	the	final	injection.	In	
the	corpus	callosum	of	Shp2	icKO	animals,	Shp2	levels	were	barely	detectable	by	
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western	blot	and	unchanged	between	Veh	Con	and	Tam	Con	animals,	thereby	
verifying	the	efficiency	of	recombination	(Figure	3-5A).	No	changes	were	observed	
in	icKO	compared	to	controls	in	the	level	of	any	of	the	major	myelin	proteins,	
including	myelin	associated	glycoprotein	(MAG),	MBP,	and	PLP	(Figure	3-5A).	
Similarly,	there	were	no	differences	observed	in	MOG	immunostaining	in	icKO	
animals	compared	to	control	groups	at	6	or	12	weeks	after	injections	(Figure	3-5B).		
	 In	order	to	assess	whether	Shp2	is	involved	in	maintaining	myelin	after	
active	myelin	production	has	ceased,	tamoxifen	or	vehicle	was	administered	once	
per	day	for	10	days	starting	at	P85.	Animals	were	sacrificed	6	weeks	after	the	final	
injection.	Again,	no	differences	were	observed	in	MOG	immunostaining	in	icKO	
brains	compared	to	controls	(Figure	3-5B,	right	column).	
Figure	3-5.	Oligodendrocyte	Shp2	is	not	necessary	for	long-term	
maintenance	of	myelination.	(A)	Representative	myelin	western	blots	of	
corpus	callosum	lysates	from	Veh	Con	(left),	Tam	Con	(center),	and	icKO	
(right)	animals	after	Shp2	induced	knockout.	(B)	Representative	MOG	
immunostaining	from	corpus	callosum	of	Veh	Con	(top	row),	Tam	Con	
(middle	row),	and	icKO	(bottom	row)	after	Shp2	induced	knockout.	Black	
scale	bars:	250	μm.	
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Figure	3-6.	Efficient	knockout	of	Shp2	from	oligodendrocytes	in	the	
spinal	cord	after	lysolecithin-induced	demyelination.	Representative	
spinal	cord	sections	from	Tam	Con,	Veh	Con,	and	icKO	were	
immunostained	with	Shp2	(green)	and	Sox10	(red)	at	14	dpl	(A-C),	21	dpl	
(D-F),	and	35	dpl	(G-I).	(J)	Quantification	of	colocalization	of	Shp2	with	
Sox10.	White	scale	bars:	100	μm.	*p-value	<	0.05.	
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Figure	3-7.	Delayed	oligodendrocyte	recruitment	and	remyelination	in	
icKO	spinal	cord.	Representative	spinal	cord	sections	from	Tam	Con,	Veh	
Con,	and	icKO	were	immunostained	with	MBP	(green)	and	Olig2	(red)	at	14	
dpl	(A-C),	21	dpl	(D-F),	and	35	dpl	(G-I).	(J)	Quantification	of	MBP	
immunostaining	as	a	percentage	of	total	dorsal	column	area.	(K)	
Quantification	of	the	number	of	Olig2-positive	oligodendrocytes	in	the	injured	
dorsal	column.	White	scale	bars:	100	μm.	*p-value	<	0.05.	
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Oligodendrocyte	Shp2	regulates	timely	differentiation	following	lysolecithin-induced	
demyelination.	Remyelination	is	the	process	of	regenerating	myelin	after	a	
demyelinating	injury	and	is	considered	one	of	the	most	robust	regenerative	
processes	in	the	adult	brain	(Franklin	and	ffrench-Constant,	2008).	Many	aspects	of	
developmental	myelination	are	conserved	in	the	remyelination	process	(Fancy	et	al.,	
2011a),	The	data	presented	above	suggest	that	Shp2	is	an	important	regulator	of	
oligodendrocyte	differentiation	and	early	stages	of	myelination	during	development.	
Therefore,	we	hypothesized	that	Shp2	could	regulate	OPC	differentiation	to	promote	
remyelination.		
Demyelination	was	induced	by	focal	injection	of	lysolecithin	into	the	dorsal	
white	matter	of	the	thoracic	spinal	cord.	Shp2	knockout	was	induced	in	
oligodendrocytes	by	daily	tamoxifen	treatment,	starting	at	3	days	post-lesion	(dpl)	
and	continuing	for	7	days.	Animals	were	analyzed	at	14	dpl	(when	new	
oligodendrocytes	differentiate	in	the	demyelinated	lesion),	21	dpl	(when	active	
remyelination	occurs),	and	35	dpl	(when	remyelination	is	normally	complete)	
(Jeffery	and	Blakemore,	1995).		
	 First,	we	confirmed	efficient	knockout	of	Shp2	from	oligodendrocytes	in	the	
de/remeylinated	lesions	(Figure	3-6).	The	majority	of	Sox10-positive	cells	also	
expressed	Shp2	in	the	dorsal	column	of	Tam	Con	(88.2%	±	3.5%)	and	Veh	Con	
(85.8%	±	4.7%)	animals,	whereas	only	12.8%	±	4.9%	of	Sox10-positive	cells	also	
expressed	Shp2	in	icKO	animals	(Figure	3-6A-C,	J).	At	21	dpl,	greater	than	80%	of	
Sox10-positive	cells	also	expressed	Shp2	in	control	groups	(83.9%	±	5.1%	and	
84.8%	±	4.8%	in	Tam	Con	and	Veh	Con	groups,	respectively),	whereas	only	21.4%	±	
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5.6%	of	Sox10-positive	cells	also	expressed	Shp2	in	icKO	animals	(Figure	3-6D-F,	J).	
Again,	at	35	dpl,	greater	than	80%	of	Sox10-positive	cells	also	expressed	Shp2	in	
control	groups	(82.3%	±	4.4%	and	80.7%	±	6.2%	in	Tam	Con	and	Veh	Con	groups,	
respectively),	whereas	only	24.4%	±	6.8%	of	Sox10-positive	cells	also	expressed	
Figure	3-8.	Delayed	differentiation	of	remyelinating	oligodendrocytes	in	
Shp2	icKO	spinal	cord.	Representative	spinal	cord	sections	from	Tam	Con,	
Veh	Con,	and	icKO	were	immunostained	with	CC1	(green)	and	Sox10	(red)	at	
14	dpl	(A-C),	21	dpl	(D-F),	and	35	dpl	(G-I).	(J)	Quantification	of	differentiated	
oligodendrocytes	(CC1,Sox10-double	positive	immunostaining)	in	the	injured	
dorsal	column.	White	scale	bars:	100	μm.	*p-value	<	0.05.	
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Shp2	in	icKO	animals	(Figure	3-6G-J).	Thus,	Shp2	was	effectively	knocked	out	from	
the	majority	of	oligodendrocytes	in	the	icKO	dorsal	column	compared	to	control	
groups.	
	 Next,	we	assessed	oligodendrocyte	recruitment	and	remyelination	by	
immunostaining	with	Olig2	and	MBP,	respectively.	At	14	dpl,	significantly	fewer	
Olig2-positive	cells	were	present	in	the	dorsal	column	of	icKO	mice	compared	to	
Tam	Con	and	Veh	Con	groups	(1301	±	51	cells/mm2,	1844	±	86	cells/mm2,	and	1777	
±	164	cells/mm2,	respectively)	(Figure	3-7A-C,	J).	At	21	dpl,	there	was	no	difference	
in	the	number	of	Olig2-positive	cells	in	the	dorsal	column	of	icKO	compared	to	Tam	
Con	and	Veh	Con	animals	(1690	±	98	cells/mm2,	1795	±	115	cells/mm2,	and	1821	±	
182	cells/mm2,	respectively)	(Figure	3-7D-F,	J).	Similarly,	at	35	dpl,	there	was	also	
no	difference	in	the	number	of	Olig2-positive	cells	in	the	dorsal	column	of	icKO	
compared	to	Tam	Con	and	Veh	Con	animals	(1861	±	74	cells/mm2,	1854	±	151	
cells/mm2,	and	1818	±	109	cells/mm2,	respectively)	(Figure	3-7G-J).	Thus,	without	
oligodendrocyte	Shp2,	there	was	a	delay	in	oligodendrocyte	recruitment	to	the	
demyelinated	lesion	at	14	dpl,	which	recovered	by	21	dpl.		
	 In	order	to	quantify	the	amount	of	remyelination	in	the	lesioned	spinal	cord,	
we	measured	the	percentage	of	the	area	of	the	dorsal	column	that	was	stained	by	
MBP.	At	14	dpl,	we	observed	equivalent	MBP	coverage	in	the	dorsal	column	in	Tam	
Con,	Veh	Con,	and	icKO	(35.2	±	3.3%,	36.2	±	3.8%,	and	35.2	±	3.4%,	respectively)	
(Figure	3-7A-C,	K).	At	21	dpl,	however,	the	icKO	animals	had	significantly	less	MBP	
coverage	compared	to	Tam	Con	and	Veh	Con	(44.2	±	3.5%,	61.6	±	2.7%,	and	61.3	±	
2.0%,	respectively)	(Figure	3-7D-F,	K).	By	35	dpl,	the	MBP	coverage	was	not	
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significantly	different	between	Tam	Con,	Veh	Con,	and	icKO	groups	(78.7	±	4.0%,	
73.1	±	4.4%,	and	63.8	±	2.9%,	respectively)	(Figure	3-7G-I,	K).	Taken	together,	these	
results	suggest	that	the	induced	knockout	of	Shp2	from	oligodendrocytes	following	
lysolecithin	demyelination	caused	an	initial	delay	in	the	recruitment	of	
oligodendrocytes	to	the	demyelinated	lesion,	resulting	in	delayed	remyelination.		
	 Finally,	we	assessed	whether	the	oligodendrocyte	differentiation	delay	
observed	in	Shp2	cKO	animals	during	development	(Figure	3-2)	was	recapitulated	
during	remyelination.	At	14	dpl,	significantly	fewer	differentiated	oligodendrocytes	
(CC1/Sox10-double	positive	cells)	were	present	in	the	dorsal	column	of	icKO	mice	
compared	to	Tam	Con	and	Veh	Con	groups	(562	±	80	cells/mm2,	1019	±	68	
cells/mm2,	and	960	±	137	cells/mm2,	respectively)	(Figure	3-8A-C,	J).	This	reduction	
in	differentiated	oligodendrocytes	persisted	until	21	dpl	(1295	±	118	cells/mm2,	
1229	±	83	cells/mm2,	and	721	±	133	cells/mm2	in	Veh	Con,	Tam	Con,	and	icKO,	
respectively)	(Figure	3-8D-F,	J).	By	35	dpl,	oligodendrocyte	differentiation	caught	up	
to	control	groups	and	there	was	also	no	difference	in	the	density	of	CC1/Sox10-
double	positive	cells	in	the	dorsal	column	of	icKO	compared	to	Tam	Con	and	Veh	
Con	animals	(1316	±	66	cells/mm2,	1576	±	125	cells/mm2,	and	1447	±	124	
cells/mm2,	respectively)	(Figure	3-8G-J).	Thus,	without	oligodendrocyte	Shp2,	there	
was	a	delay	in	oligodendrocyte	recruitment	to	the	demyelinated	lesion	at	14	dpl,	
which	recovered	by	21	dpl.	Taken	together,	these	results	suggest	that	
oligodendrocyte	Shp2	influences	remyelination	in	the	spinal	cord	by	promoting	
timely	oligodendrocyte	recruitment	and	differentiation.	
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Discussion	
	
	 In	the	current	study,	sing	in	vivo	conditional	and	inducible	knockout	mouse	
genetics	approaches	we	present	three	primary	finding	regarding	the	function	of	
Shp2	in	oligodendrocytes.	First,	we	verified	previous	reports	suggesting	a	role	of	
Shp2	in	regulating	oligodendrocyte	differentiation	during	development	using	a	
different	transgenic	cre	mouse	line	(Zhu	et	al.,	2010)	and	Figure	3-2).	Second,	we	
showed	that	Shp2	may	act	as	a	negative	regulator	during	early	stages	of	CNS	
myelination	and	that	these	effects	are	mediated	through	Shp2	inhibition	of	FAK.	
Furthermore,	these	effects	on	myelination	are	dispensable	for	long-term	myelin	
maintenance.	Third,	we	showed	that	oligodendrocyte	Shp2	was	necessary	for	timely	
remyelination	following	lysolecithin-induced	demyelination	by	influencing	
oligodendrocyte	recruitment	and	differentiation.	
	 Conflicting	data	regarding	the	effect	of	Shp2	on	oligodendrocyte	
differentiation	was	presented	in	two	studies	using	cultured	oligodendrocytes,	where	
one	study	claimed	Shp2	promoted	maturation	of	oligodendrocytes	(Liu	et	al.,	
2011b)	and	the	other	that	Shp2	inhibited	maturation	and	maintained	OPCs	in	a	
proliferative	state	(Kuo	et	al.,	2010).	Subtle	differences	in	experimental	procedures	
could	account	for	the	discrepancy	between	these	two	reports.	Zhu	et	al.	(2010)	
utilized	the	Olig1-cre	mouse	to	delete	Shp2	from	oligodendrocytes	and	were	able	to	
show	that	in	addition	to	regulating	oligodendrocyte	generation	in	the	developing	
spinal	cord,	the	loss	of	Shp2	inhibited	oligodendrocyte	differentiation.	This	study	
did	not	report	any	data	from	the	brains	of	their	transgenic	animals.	Another	study	
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examined	Shp2	function	in	oligodendrocytes	in	the	brain	using	the	Olig2-cre	
transgenic	mouse	but	did	not	examine	differentiation	effects	(Ehrman	et	al.,	2014).	
The	data	presented	in	this	report	suggest	that	oligodendrocyte	Shp2	in	the	
developing	brain	also	promotes	differentiation,	consistent	with	its	role	in	the	
developing	spinal	cord.	
	 Previous	reports	were	limited	in	examining	oligodendrocyte	Shp2	function	
during	myelination	due	to	early	postnatal	lethality.	Both	sets	of	animals	only	lived	to	
3	weeks	of	age,	and	data	regarding	myelination	in	the	two	conditional	knockout	
strains	was	only	presented	at	P15	in	both	reports	(Zhu	et	al.,	2010;	Ehrman	et	al.,	
2014).	Using	the	CNP-cre	transgenic	line,	we	were	able	to	extend	the	lifespan	of	
these	animals	by	at	least	one	week,	allowing	for	a	more	detailed	characterization	of	
Shp2’s	role	during	late	postnatal	myelination.	Our	early	myelination	data	was	
consistent	with	previous	reports,	demonstrating	reduced	myelination	during	the	
first	two	weeks	of	age.	Interestingly,	we	showed	a	unique	phenotype	at	P28	where	
cKO	animals	had	fewer	myelinated	axons	with	thicker	myelin	sheaths.	This	is	in	line	
with	our	initial	hypothesis	that	Shp2	acts	as	a	negative	regulator	of	myelination.	
The	signaling	mechanisms	responsible	for	the	increased	myelin	thickness	
observed	were	unexpected.	The	increased	myelin	per	axon	was	not	due	to	increased	
Akt/mTOR	or	ERK	signaling,	two	signaling	cascades	that	have	previously	been	
shown	to	regulate	myelin	thickness	(Flores	et	al.,	2008;	Ishii	et	al.,	2013).	Similarly,	
Ehrman	et	al.	(2014)	demonstrated	that	a	Shp2	gain	of	function	mutation	expressed	
in	oligodendrocytes,	which	increased	the	levels	of	ERK	signaling,	resulted	in	fewer	
numbers	of	myelinated	axons	with	myelin	decompaction	abnormalities	but	not	
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increased	myelin	production.	Thus,	elevated	ERK	signaling	in	some	contexts	in	not	
sufficient	to	cause	myelin	overproduction.		
Instead,	we	observed	significantly	higher	levels	of	FAK	signaling	coincident	
with	the	increased	production	of	myelin.	FAK	is	a	known	substrate	of	Shp2	(Huang	
et	al.,	2011;	Hartman	et	al.,	2013)	and	has	been	shown	to	influence	process	
extension	during	oligodendrocyte	differentiation	(Hoshina	et	al.,	2007)	and	the	
conditional	knockout	of	FAK	from	oligodendrocytes	results	in	decreased	CNS	
myelination	(Forrest	et	al.,	2009).	Our	data	is	consistent	with	these	previous	reports	
and	we	suggest	a	model	in	which	loss	of	Shp2	from	oligodendrocytes	during	early	
myelination	causes	increased	FAK	phosphorylation	and	excess	myelin	production.	
The	downstream	effectors	of	FAK	signaling,	and	how	those	effectors	influence	
myelination,	remain	unknown.	
While	Shp2	loss	during	early	myelination	resulted	in	increased	myelin	
production,	the	induced	knockout	of	Shp2	during	or	after	active	myelination	was	
insufficient	to	cause	long-term	changes	in	myelin	production.	These	data	suggest	
that	Shp2	is	dispensable	for	myelin	maintenance.	It	is	possible	that	induced	Shp2	
knockout	caused	an	initial	increase	in	myelin	production	that	was	later	
appropriately	scaled	down	by	6-weeks	post-injections.	However,	this	is	unlikely	due	
to	the	long	half-life	and	slow	turnover	of	myelin	(Quarles	et	al.,	2006).	Another	
possibility	is	that	Shp2	provides	transient	regulation	of	myelination,	while	another	
currently	unknown	protein	provides	sustained	downregulation	of	myelination.	The	
PNS	utilizes	this	strategy	of	multiple	negative	regulators,	with	Dlg1	serving	as	a	
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transient	regulator	and	DDIT4	as	a	sustained	regulator	(Cotter	et	al.,	2010;	Noseda	
et	al.,	2013).	
Finally,	we	are	the	first	to	show	that	oligodendrocyte	Shp2	plays	a	functional	
role	in	CNS	remyelination.	Both	the	recruitment	and	differentiation	of	
oligodendrocytes	in	the	demyelinated	spinal	cord	were	delayed	by	Shp2	deletion,	
resulting	in	delayed	remyelination.	The	downstream	signaling	events	that	caused	
these	effects	remain	to	be	determined.	Similar	delays	in	remyelination	were	
observed	in	ERK2	conditional	knockout	animals	and	were	attributed	to	decreased	
translation	of	MBP	(Michel	et	al.,	2015).	Thus,	it	is	conceivable	that	while	Shp2	
knockout	does	not	have	a	great	affect	on	ERK	signaling	during	development,	it	could	
influence	ERK	signaling	to	control	MBP	translation	during	myelin	regeneration.	
	 In	conclusion,	Shp2	is	an	important	mediated	of	oligodendrocyte	
differentiation	and	myelination,	both	during	developmental	myelination	as	well	as	
myelin	regeneration.	We	provide	important	insight	into	the	signaling	mechanisms	
regulating	myelination	and	propose	that	Shp2	acts	as	a	transient	brake	to	the	early	
myelination	process.	Furthermore,	the	role	of	Shp2	in	regulating	differentiation	of	
oligodendrocytes	following	demyelination	has	important	therapeutic	implications,	
as	differentiation	failure	is	a	pathological	feature	in	multiple	sclerosis	and	thought	
to	contribute	to	remyelination	failure	as	the	disease	progresses	(Chang	et	al.,	2002).	
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CHAPTER	IV	
ACTIVELY	MYELINATING	OLIGODENDROCYTES	IN	THE	PEDIATRIC	MOUSE	
BRAIN	ARE	RESISTANT	TO	ISCHEMIA	INDUCED	DAMAGE	
	
Summary	
	
White	matter	injury	following	ischemic	stroke	is	a	major	cause	of	functional	
disability.	Injury	to	both	myelinated	axons	and	oligodendrocytes,	the	myelin	
producing	cells	in	the	central	nervous	system,	occurs	in	experimental	models	of	
ischemic	stroke.	Age-related	changes	in	white	matter	vulnerability	to	ischemia	have	
been	extensively	studied	and	suggest	that	both	the	perinatal	and	the	aged	periods	
are	times	of	increased	white	matter	vulnerability.	However,	sensitivity	of	white	
matter	following	stroke	in	the	pediatric	brain	has	not	been	evaluated.	Interestingly,	
the	late	pediatric	period	is	an	important	developmental	stage,	as	it	is	the	time	of	
maximal	myelination.	The	current	study	demonstrates	that	neurons	in	late	pediatric	
striatum	are	vulnerable	to	ischemic	damage,	with	neuronal	injury	being	comparable	
in	pediatric	and	adult	mice	following	ischemia.	By	contrast,	actively	myelinating	
striatal	oligodendrocytes	in	the	pediatric	brain	are	resistant	to	ischemia,	whereas	
adult	oligodendrocytes	are	quite	sensitive.	As	a	result,	myelin	sheaths	are	
remarkably	intact	and	axons	survive	well	in	the	injured	striatum	of	late	pediatric	
mice.	In	addition	to	relative	resistance	of	pediatric	white	matter,	we	observe	very	
different	glial	responses	in	pediatric	and	adult	mice	following	cerebral	ischemia,	
including	differences	in	astrogliosis,	fibrosis,	NG2-cell	reactivity,	and	vascular	
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integrity.	Together,	these	responses	lead	to	long-term	preservation	of	brain	
parenchyma	in	pediatric	mice	compared	to	severe	tissue	loss	and	scarring	in	adult	
mice.	Overall,	the	current	study	suggests	that	equivalent	ischemic	insults	may	result	
in	less	functional	deficit	in	children	compared	to	adults	and	an	environment	more	
conducive	to	long-term	recovery.	
	
Introduction	
	
	 Ischemic	stroke	impacts	both	white	and	gray	matter	in	the	human	brain.	
However,	most	experimental	stroke	research	has	focused	on	ischemia	in	gray	
matter,	with	less	attention	on	its	impact	in	white	matter.	White	matter	damage	has	
local	effects	at	the	primary	site	of	damage,	as	well	as	distal	effects	on	brain	regions	
with	which	white	matter	axons	communicate.	Age-dependent	vulnerability	to	stroke	
has	been	noted.	Both	early	post-natal	as	well	as	aging	white	matter	are	highly	
sensitive	to	ischemia,	and	unique	molecular	mechanisms	underlie	these	differences	
(Baltan	et	al.,	2008;	Back	and	Rosenberg,	2014).	It	is	imperative	to	understand	how	
ischemia	affects	white	matter,	and	how	these	effects	change	during	all	stages	of	
brain	development.	
Pediatric	arterial	ischemic	stroke	affects	up	to	1,000	children	in	the	United	
States	each	year,	with	a	vast	majority	of	surviving	children	suffering	long-term	
neurological	deficit	with	varying	degrees	of	disability	(Roach	et	al.,	2008).	Initial	
clinical	studies	suggest	that	recovery	from	stroke	is	greater	in	older	juvenile	
patients	compared	to	strokes	occurring	shortly	after	birth	(Pavlovic	et	al.,	2006;	
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Everts	et	al.,	2008;	Westmacott	et	al.,	2010;	Allman	and	Scott,	2013)	or	in	adulthood	
(Anderson	et	al.,	2011;	Ellis	et	al.,	2014).	A	similar	pattern	of	age-related	stroke	
recovery	exists	in	rodents	(Yager	et	al.,	2006;	Saucier	et	al.,	2007).	In	order	to	
understand	the	mechanisms	and	responses	that	may	be	unique	to	the	juvenile	
developmental	time	period,	we	utilized	a	recently	developed	mouse	model	of	
pediatric	arterial	ischemic	stroke	(Herson	et	al.,	2013).	The	effects	of	ischemia	
during	this	developmental	period	have	been	strikingly	understudied.	The	current	
studies	demonstrate	that	ischemia	in	late	pediatric	mice	is	far	less	damaging	to	
white	matter	compared	to	adults.		
The	late	juvenile	period	is	important,	as	it	is	the	peak	of	central	nervous	
system	(CNS)	myelination.	Oligodendrocytes	are	the	myelin	producing	cells	in	the	
CNS	and	a	major	cellular	constituent	of	white	matter,	along	with	myelinated	axons	
and	white	matter	astrocytes.	Oligodendrocytes	are	vulnerable	to	cerebral	ischemia	
at	multiple	stages	of	development.	Immature,	pre-myelinating	oligodendrocytes	are	
highly	susceptible	to	ischemic	cell	death	following	neonatal	ischemia	(Back	et	al.,	
2002a;	2002b),	whereas	in	the	adult,	it	is	the	mature	oligodendrocytes	that	are	
damaged	by	ischemia,	leading	to	myelin	loss,	and	eventually	axonal	injury	(Dewar	et	
al.,	2003).	Myelinated	axons	also	display	age-dependent	sensitivity	to	ischemic	
injury,	with	developing	white	matter	axons	having	high	susceptibility	(McCarran	
and	Goldberg,	2007).		
	 In	active	myelination,	oligodendrocytes	generate	massive	amounts	of	
membrane,	estimated	to	produce	a	myelin	surface	area	over	100	times	the	surface	
area	of	the	cell	(Pfeiffer	et	al.,	1993).		At	this	time,	these	cells	have	very	high	
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metabolic	rates	and	are	sensitive	to	prolonged	deprivation	of	energy	substrates	
(Yan	and	Rivkees,	2006;	Rinholm	et	al.,	2011).	Therefore,	we	would	expect	that	
actively	myelinating	oligodendrocytes	would	be	particularly	vulnerable	to	ischemic	
injury	during	this	time	point.	In	order	to	test	this	hypothesis,	we	examined	the	glial	
responses	following	experimentally-induced	stroke	in	juvenile	mice	(20-25	days	
old).	
	 Here,	we	show	unexpectedly	that	oligodendrocytes	in	the	late	pediatric	brain	
are	remarkably	resistant	to	ischemic	injury,	which	seems	to	be	due	to	a	more	robust	
response	to	oxidative	stress.	We	also	show	that	oligodendrocyte	progenitor	cells	
(OPCs,	NG2	progenitor	cells),	astrocytes,	pericytes,	and	blood	vessels	respond	
differently	to	pediatric	stroke	compared	to	adult	stroke.	These	differing	responses	
to	ischemia	could	underlie	the	greater	degree	of	recovery	observed	in	pediatric	
stroke	survivors.		
	
Experimental	procedures	
	
Animals.	All	experimental	protocols	were	approved	by	the	Institutional	
Animal	Care	and	Use	Committee	at	the	University	of	Colorado	School	of	Medicine,	
and	conformed	to	the	National	Institutes	of	Health	guidelines	for	the	care	and	use	of	
animals	in	research.	Male	C57Bl/6	mice	were	used	for	most	studies	(Charles	River,	
Inc);	male	PLP-EGFP	transgenic	mice	(Mallon	et	al.,	2002)	were	also	used.	
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Middle	Cerebral	Artery	Occlusion	(MCAo).	MCAo	surgeries	were	performed	by	
Himmat	Grewal	and	Frank	Strnad	in	Paco	Herson’s	lab	at	the	University	of	Colorado	
Anschutz	Medical	Campus.	MCAo	was	induced	by	methods	previously	published	for	
pediatric	male	mice	at	postnatal	day	(P)	20	to	25	(Herson	et	al.,	2013)	or	adult	male	
mice	at	8-12	weeks	old	(Jia	et	al.,	2011).	Briefly,	cerebral	ischemia	was	induced	for	
45	minutes	of	reversible	MCAo	via	the	intraluminal	suture	method	under	isoflurane	
anesthesia.	Adequacy	of	MCAo	was	confirmed	by	laser	Doppler	flowmetry	measured	
over	the	ipsilateral	parietal	cortex.	The	occluding	suture	was	then	removed,	thereby	
restoring	blood	flow	to	the	affected	region.	Mice	were	monitored	closely	following	
the	surgical	procedure	and	were	sacrificed	at	the	following	time	points:	24	hours,	3	
days,	7	days,	and	30	days.	
	
Infarct	Volume	Analysis.	Twenty-four	hours	after	reperfusion	adult	and	
pediatric	mice	were	deeply	anesthetized	with	isoflurane	and	brains	removed	for	
analysis	of	infarct	volume.	Each	brain	was	sliced	into	five	2	mm	thick	coronal	
sections	and	immediately	placed	in	a	1.2%	solution	of	2,3,5-triphenyltetrazolium	
chloride	(TTC,	Sigma)	for	30	minutes	at	37°C	followed	by	fixation	in	10%	formalin	
for	24	hours.	Each	aspect	of	all	stained	coronal	slices	was	photographed	using	a	
digital	camera;	infarction	was	measured	with	digital	image	analysis	software	
(ImageJ)	and	integrated	across	all	5	slices.	To	account	for	the	effect	of	edema,	the	
infarcted	volume	was	estimated	and	expressed	as	a	percentage	of	the	contralateral	
structure.	
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Immunohistochemistry.	After	the	reperfusion	period,	mice	were	anesthetized	
and	tissue	was	fixed	by	transcardial	perfusion	with	PBS	followed	by	4%	
paraformaldehyde.	The	brain	was	dissected,	postfixed	overnight,	and	transferred	to	
cryoprotection	solution	(20%	glycerol	in	0.1	M	Sorenson’s	buffer,	pH	7.6).	The	
immunohistochemistry	protocol	was	adapted	from	previously	described	studies	
(Trapp	et	al.,	1997).	Brains	were	sectioned	at	30	μm	on	a	sliding	microtome	and	
sections	were	stored	at	4°C	in	cryostorage	solution	(30%	ethylene	glycol,	30%	
sucrose,	and	1%	PVP-40	in	0.1	M	Sorenson’s	buffer).	Free-floating	sections	were	
washed	in	PBS	and	antigen	retrieval	was	performed	with	10	mM	sodium	citrate	(pH	
6.0)	+	0.05%	Tween-20	for	10	minutes	at	550	W	in	a	PELCO	BioWave	Pro	tissue	
processor	(Ted	Pella).	Sections	were	then	washed	in	PBS,	permeabilized	with	0.3%-
10%	Triton	X-100	(dependent	on	specific	antibodies),	blocked	with	5%	normal	
donkey	serum,	and	incubated	with	primary	antibody	for	1-3	days	at	4°C.	The	
following	primary	antibodies	were	used:	mouse	anti-CC1	(Calbiochem);	rabbit	anti-
fibrinogen	(Abcam);	chicken	anti-GFAP	(Abcam);	rabbit	anti-GSTπ	(ENZO);	rabbit	
anti-MOG	(Abcam);	rabbit	anti-NG2	(a	gift	from	Dr.	William	Stallcup,	Sanford-
Burnham	Institute);	rabbit	anti-Olig2	(a	gift	from	Dr.	Charles	Stiles,	Harvard	
University);	rabbit	anti-PDGFRα	(Santa	Cruz);	mouse	anti-NeuN	(Millipore);	rat	
anti-PLP/DM20	(clone	AA3,	(Yamamura	et	al.,	1991));	mouse	anti-SMI32	(Covance);	
mouse	anti-SMI94	(MBP,	Covance);	goat	anti-Sox10	(Santa	Cruz);	rat	anti-CD13	
(AbD	Serotec);	rabbit	anti-Glut-1	(Thermo	Scientific);	rabbit	anti-nitrotyrosine	
(Santa	Cruz);	mouse	anti-HO-1-1	(Abcam).	After	washing	with	PBS,	sections	were	
incubated	with	the	appropriate	secondary	antibodies	(Jackson	ImmunoResearch)	
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for	2	hours	at	room	temperature	and	mounted	on	glass	slides	in	Vectashield	
Mounting	Media	(Vector	Laboratories).	TUNEL	staining	was	performed	according	to	
manufacturer’s	protocol	(Roche),	followed	by	antibody	co-staining,	as	described	
above.	Diaminobenzidine	(DAB)	staining	was	performed	according	to	
manufacturer’s	protocol	(Avidin-Biotin	Complex	Kit	and	DAB	Kit,	Vector	
Laboratories).	Fluorescent	images	were	acquired	using	a	Leica	TCS	SP5	II	confocal	
microscope	using	identical	imaging	parameters	for	ipsilateral	and	contralateral	
images.	DAB	images	were	acquired	with	a	Leica	DMR	microscope	and	DFC290HD	
digital	camera.	
	
Cell	Counting.	Cells	were	quantified	from	images	acquired	in	the	lateral	
aspect	of	the	injured	(ipsilateral)	striatum	and	corresponding	images	in	the	
uninjured	(contralateral)	striatum.	At	least	two	images	were	taken	from	the	
ipsilateral	and	contralateral	striatum	per	stained	section,	and	at	least	two	sections	
Figure	4-1.	Brain	regions	of	interest	following	MCAo.	.	Representative	
coronal	section	showing	the	location	of	the	lesioned	tissue	of	interest	(pink	
area).	Images	in	this	study	were	taken	in	the	ipsilateral	and	contralateral	
striatum	(red	boxes).	Black	scale	bar:	1	mm.	
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were	stained	per	animal	(Figure	4-1).	Four	animals	per	group	were	analyzed.	Cell	
death	was	quantified	by	positive	TUNEL	staining.	NeuN	positive	neurons	were	
quantified.	Olig2	or	Sox10-positive	oligodendrocytes	were	quantified.	
Oligodendrocyte	precursor	cells	were	identified	by	co-expression	of	PDGFRα	and	
Sox10.	Mature	oligodendrocytes	were	identified	by	co-expression	of	CC1	and	Sox10.	
The	Cell	Counter	plug-in	on	Fiji	software	(Schindelin	et	al.,	2012)	was	used	for	all	
cell	count	analyses.		
	
Blood	vessel	analysis.	Blood	vessels	were	analyzed	in	two	ways.	The	lengths	of	
each	blood	vessel	segment	were	traced	using	Glut-1	immunostaining	and	measured	
using	the	Measure	and	Label	plug-in	on	Fiji	software.	The	individual	lengths	were	
summed	to	attain	the	total	vessel	length	for	each	image.	Second,	a	MATLAB	program	
was	written	in-house	(courtesy	of	Elizabeth	Gould)	to	measure	the	number	of	
connected	objects	(corresponding	to	the	number	of	individual	blood	vessel	
segments)	and	the	area	of	co-localization	between	CD13	and	Glut-1	(corresponding	
to	the	amount	of	vessel-associated	pericytes).	The	images	were	adjusted	for	non-
uniform	background	staining	and	positive	pixels	were	identified	using	a	set	
threshold.	The	area	covered	by	positive	pixels	was	quantified	in	each	channel.	
Individual	blood	vessel	segments	were	quantified	by	counting	the	number	of	
connected	objects	with	more	than	2	pixels.	To	facilitate	the	identification	of	
individual	blood	vessel	segments,	the	staining	boundaries	were	filled	in	using	the	
“imfill”	function,	and	connected	objects	were	quantified.	At	least	four	images	were	
measured	per	animal,	with	four	animals	per	group.		
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Electron	microscopy.	Animals	were	perfused	with	modified	Karnovsky’s	
fixative	(2%	paraformaldehyde/2.5%	glutaraldehyde)	in	phosphate	buffer,	pH	7.4.	
The	brain	was	dissected	and	stored	in	postfix	until	embedding.	Striatal	tissue	was	
isolated	from	1mm	coronal	slices	between	1.00	and	-0.40	of	Bregma.	Tissue	was	
postfixed	in	1%	osmium	tetroxide,	dehydrated	in	graded	acetone,	and	resin	
embedded	in	Embed	812	(Electron	Microscopy	Services)	using	a	PELCO	BioWave	
Pro	tissue	processor	(Ted	Pella).	Striatal	pieces	were	oriented	such	that	sections	
could	be	cut	in	a	coronal	plane	to	visualize	myelinated	axon	fibers.	Ultrathin	
sections	(80	nm)	were	mounted	on	copper	grids,	stained	with	uranyl	acetate	and	
lead	citrate,	and	viewed	at	80	kV	on	a	Tecnai	G2	transmission	electron	microscope	
(FEI).		
Figure	4-2.	No	age	difference	in	infarct	volume	following	MCAo.	
Representative	TTC-stained	brain	slices	in	adult	(A)	and	pediatric	(B)	mice.	
(C)	Quantification	of	infarct	volume	in	adult	(n=8)	and	pediatric	(n=7)	mice.	
Data	were	presented	as	%	infarct	relative	to	contralateral	structure.	
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G-ratio	analysis.	G-ratios	of	myelinated	fibers	were	calculated	as	the	ratio	of	
the	diameter	of	the	axon	to	the	diameter	of	the	myelinated	fiber.	Diameters	were	
derived	by	measuring	the	respective	perimeters	using	FIJI	software.	A	minimum	of	
Figure	4-3.	Cell	death	after	MCAo.	Ischemic	(ipsilateral)	and	control	
(contralateral)	pediatric	(A-D)	and	adult	(E-H)	striatum	sections	were	stained	
for	dying	cells	(TUNEL,	red),	neurons	(NeuN,	green),	and	oligodendrocytes	
(Olig2,	blue).	(I)	Quantification	of	dying	cells	in	the	ipsilateral	striatum	from	
pediatric	(dark	bar)	and	adult	(open	bar)	samples.	(J,	L)	Quantification	of	
remaining	neurons	in	ipsilateral	(Ipsi,	open	bar)	versus	contralateral	(Contra,	
dark	bar)	striatum	from	pediatric	(J)	and	adult	(L)	samples.	(K,	M)	
Quantification	of	oligodendrocytes	in	ipsilateral	(Ipsi,	open	bar)	versus	
contralateral	(Contra,	dark	bar)	striatum	from	pediatric	(K)	and	adult	(M)	
samples.	White	scale	bars:	100	μm.	*p-value	<	0.05.	
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100	axons	per	condition	were	quantified,	and	samples	were	analyzed	from	four	
animals	per	experimental	group.		
	
Statistical	analysis.	Unpaired,	two-tailed	Student’s	t-test	was	used	to	calculate	
statistical	significance	between	ipsilateral	and	contralateral	regions	within	each	
group,	with	a	p-value	less	than	0.05	designated	as	statistically	significant.	Graphs	
represent	the	mean	±	SEM.	Graphs	were	created	and	statistics	were	performed	
using	Prism	6	software	(www.graphpad.com).	
	
Results	
	
Cell	death,	neuronal	loss,	and	oligodendrocyte	preservation	after	pediatric	
MCAo.	The	current	studies	were	undertaken	to	assess	the	relative	damage	induced	
by	MCAo	in	late	pediatric	mice	relative	to	adult	mice.	Male	adult	(2-3	months)	and	
pediatric	(P20-25)	mice	were	subjected	to	45	minutes	of	MCAo,	and	infarct	volume	
was	analyzed	24	hours	after	reperfusion.	Adult	and	pediatric	mice	exhibited	nearly	
identical	ischemic	damage	after	MCAo,	with	edema-corrected	hemispheric	infarct	
volumes	of	46	±	4.2%	and	43	±	4.5%,	respectively	(Figure	4-2).	Ischemic	damage	
was	also	not	different	between	ages	in	the	cortex	or	the	striatum.	To	characterize	
the	cellular	response	and	extend	the	observation	time	beyond	the	acute	stage,	adult	
and	pediatric	mice	were	subjected	to	45	min	MCAo	and	brains	analyzed	by	
immunohistochemistry	at	24	hours,	3	or	7	days	after	reperfusion.	Due	to	the	well-
established	sensitivity	of	both	neurons	and	oligodendrocytes	to	hypoxia/ischemia	
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(Valeriani	et	al.,	2000;	Back	et	al.,	2002a),	we	analyzed	the	effects	of	MCAo	on	the	
survival	of	neurons	and	oligodendrocytes.	Sections	from	pediatric	or	adult	MCAo	
mice	were	stained	with	NeuN,	a	marker	of	neuronal	nuclei;	Olig2,	a	transcription	
factor	expressed	by	all	oligodendrocyte	lineage	cells;	and	TUNEL	(terminal	
deoxynucleotidyl	transferase	dUTP	nick	end	labeling),	to	detect	DNA	fragmentation	
in	apoptotic	cells	(Figure	4-3).	Cell	death	was	not	observed	in	the	contralateral	
striatum	of	either	pediatric	or	adult	mice,	where	many	NeuN-positive	and	Olig2-
positive	cells	were	detected	(Figure	4-3A,	E).	In	both	pediatric	and	adult	mice,	cell	
death	was	observed	in	the	ipsilateral	striatum	as	early	as	24	hours	post-MCAo	
(Figure	4-3B,	F,	I).	Cell	death	peaked	at	3	days	post-MCAo	(Figure	4-3C,	G,	I),	but	was	
still	occurring	at	7	days	post-MCAo	(Figure	4-3D,	H,	I).	There	were	no	statistically	
significant	differences	in	the	number	of	TUNEL-positive	cells	between	pediatric	and	
adult	samples	at	any	time	point	(Figure	4-3I).	Together,	these	results	suggest	that	
acute	ischemic	injury,	as	assessed	by	TTC	staining,	and	cell	death,	as	determined	by	
TUNEL	staining,	were	comparable	between	pediatric	and	adult	mice	after	45	
minutes	of	reversible	MCAo.	
	 At	the	same	time	that	there	were	dying	cells,	the	number	of	NeuN-positive	
neurons	dramatically	decreased	in	the	injured	striatum	after	MCAo	in	both	pediatric	
and	adult	mice.	In	pediatric	mice,	the	neuronal	population	in	the	ipsilateral	striatum	
was	severely	reduced	at	24	hours	post-MCAo	compared	to	the	contralateral	
hemisphere	(Figure	4-3B,	J).	The	neuronal	population	decreased	further	after	3	days	
post-MCAo	(Figure	4-3C,	J)	and	remained	low	at	7	days	post-MCAo	(Figure	4-3D,	J).	
In	adult	mice,	the	neuronal	population	in	the	ipsilateral	striatum	was	also	severely		
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Figure	4-4.	Oligodendrocytes	are	preserved	in	pediatric,	but	not	adult,	
tissue	after	MCAo.	Ischemic	(ipsilateral)	and	control	(contralateral)	
pediatric	(A-D)	and	adult	(E-H)	sections	were	immunostained	to	detect	OPCs	
(PDGFRα	,	green),	total	oligodendrocytes	(Sox10,	red),	and	mature	
oligodendrocytes	(CC1,	blue).	(I,	K)	OPCs,	identified	by	double	staining	with	
PDGFRα	and	Sox10,	were	quantified	in	pediatric	(I)	and	adult	(K)	striatum	
from	ischemic	(Ipsi,	open	bars)	and	control	(Contra,	dark	bars)	samples.	(J,	L)	
Mature	oligodendrocytes	were	identified	by	double	staining	with	CC1	and	
Sox10,	and	quantified	in	pediatric	(J)	and	adult	(L)	striatum	from	ischemic	
(Ipsi,	open	bars)	and	control	(Contra,	dark	bars)	samples.	(M,	N)	High	
magnification	images	of	PLP-EGFP	expressing	oligodendrocytes	in	the	
ipsilateral	striatum	24	hours	after	MCAo	demonstrating	preserved	
oligodendrocyte	morphology	and	intact	myelin	processes	in	pediatric	cells	
(M)	but	not	adult	cells	(N).	White	scale	bars:	100	μm.	Green	scale	bars:	10	μm.	
*p-value	<	0.05.	
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reduced	compared	to	the	contralateral	hemisphere	at	24	hours	post-MCAo	(Figure	
4-3F,	L).	The	neuronal	population	in	the	adult	striatum	decreased	further	at	3	days	
post-MCAo	(Figure	4-3G,	L)	and	it	was	almost	completely	abolished	at	7	days	post-
Figure	4-5.	Myelin	damage,	axon	pathology,	and	long-term	tissue	loss	
after	MCAo.	Electron	micrographs	of	myelinated	striatal	axons	from	control	
and	ischemic	pediatric	(A-D)	and	adult	(E-H)	mice.	(I,	J)	At	7	days	post-MCAo,	
axonal	pathology	and	myelin	were	determined	by	SMI32	(red)	and	PLP	(blue)	
immunoreactivity	in	pediatric	and	adult	mice,	respectively.	(K,	L)	At	30	days	
post-MCAo,	tissue	was	stained	for	myelin	with	myelin-oligodendrocyte	
glycoprotein	(MOG)	antibody.	Scale	bars	in	A-H:	2	μm;	I-J:	10	μm;	K-L:	1	mm.	
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MCAo	(Figure	4-3H,	L).	Together,	these	results	suggest	that	the	neuronal	loss	in	the	
striatum	was	similar	for	pediatric	and	adult	mice	after	MCAo,	and	that	neuronal	loss	
occurred	rapidly.		
	 Quite	unexpectedly,	when	oligodendrocyte	lineage	cells	were	quantified	after	
MCAo,	very	few	Olig2-positive	oligodendrocyte	lineage	cells	in	the	pediatric	
striatum	were	lost,	i.e.,	they	appeared	highly	resistant	to	ischemic	damage.	At	24	
hours	post-MCAo,	no	change	in	the	number	of	Olig2-positive	cells	was	noted	in	the	
ipsilateral	striatum	compared	to	the	contralateral	striatum	(Figure	4-3B,	K).	The	
number	of	oligodendrocyte	lineage	cells	was	significantly	increased	3	days	post-
MCAo	(Figure	4-3C,	K)	and	the	number	of	Olig2-positive	cells	remained	elevated	at	7	
days	post-MCAo	(Figure	4-3D,	K).	Adult	oligodendrocytes,	on	the	other	hand,	were	
quite	sensitive	to	ischemic	injury.	A	significant	decrease	in	the	number	of	Olig2-
positive	cells	was	observed	in	the	ipsilateral	striatum	compared	to	the	contralateral	
striatum	at	24	hours	post-MCAo	(Figure	4-3F,	M)	and	the	oligodendrocyte	
population	remained	low	at	3	days	post-MCAo	(Figure	4-3G,	M).	At	7	days	post-
MCAo	in	adult	mice,	a	significant	increase	in	the	oligodendrocyte	population	was	
seen	in	the	ipsilateral	striatum	compared	to	the	corresponding	contralateral	region	
(Figure	4-3H,	M).	Together,	these	results	suggest	that	oligodendrocytes	in	the	
pediatric	brain	are	resistant	to	ischemic	injury,	whereas	oligodendrocytes	in	the	
adult	brain	are	highly	sensitive	to	the	same	ischemic	insult.		
	
Oligodendrocyte	precursor	cells	responses	in	ischemic	tissue	after	MCAo.	
Because	Olig2	labels	both	oligodendrocyte	progenitor	cells	(OPCs)	and	mature	
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oligodendrocyte	populations,	we	more	closely	examined	the	impact	of	ischemia	on	
each	of	these	populations	using	stage-specific	oligodendrocyte	antigenic	markers.	
Pediatric	and	adult	tissues	were	immunolabeled	with	PDGFRα,	a	marker	for	OPCs;	
CC1,	a	marker	for	mature	oligodendrocytes;	and	Sox10,	a	transcription	factor	
expressed	by	both	populations	(Figure	4-4A-H).	In	pediatric	mice,	OPCs	were	
unaffected	by	ischemia	in	the	ipsilateral	striatum	at	24	hours	post-MCAo	relative	to	
the	contralateral	striatum	(Figure	4-4B,	I).	OPC	numbers	were	significantly	elevated	
Figure	4-6.	Differential	fibrotic	and	astrogliotic	patterns	following	MCAo	
in	pediatric	versus	adult	mice.	Ischemic	and	control	pediatric	(A-D)	and	
adult	(E-H)	sections	were	immunostained	to	detect	fibrinogen	(green),	GFAP	
(red),	and	MBP	(blue).	Scant	fibrinogen	immunoreactivity	was	observed	in	
the	injured	pediatric	striatum	at	any	time	point	examined	(A-D).	Fibrinogen	
deposition	occurs	as	early	as	24	hours	in	the	adult	striatum	(F),	with	large	
deposits	surrounding	blood	vessels	at	3	days	(G,	arrowheads).	By	7	days,	a	
large	sheet	of	fibrinogen	was	observed	throughout	the	core	of	the	lesion	in	
adult	tissue	(H).	Astrogliosis	was	observed	surrounding	the	ischemic	core	in	
both	pediatric	and	adult	striatum	at	3	days	post-stroke	(C	and	G,	
respectively).	Peri-infarct	astrogliosis	is	maintained	in	adults	at	7	days	post-
stroke	(H),	whereas	diffuse	astrogliosis	throughout	the	injured	striatum	is	
observed	in	pediatric	mice	(D).	White	scale	bars:	250	μm.	
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in	the	injured	pediatric	striatum	at	3	days	post-MCAo	compared	to	the	
corresponding	contralateral	striatum	(Figure	4-4C,	I),	and	they	remained	elevated	at	
7	days	post-MCAo	(Figure	4-4D,	I).		
	 By	contrast,	adult	OPCs	were	severely	affected	by	MCAo	during	the	early	
period	after	ischemia.	At	24	hours	post-MCAo,	the	number	of	surviving	OPCs	was	
significantly	decreased	in	the	ipsilateral	striatum	relative	to	contralateral	striatum	
(Figure	4-4F,	K)	and	remained	significantly	decreased	at	3	days	post-MCAo	(Figure	
4-4G,	K).	At	7	days	post-MCAo,	however,	the	number	of	OPCs	in	the	injured	striatum	
Figure	4-7.	Differential	NG2-cell	response	following	MCAo	in	pediatric	
versus	adult	mice.	Ischemic	and	control	pediatric	(A-D)	and	adult	(E-H)	
sections	were	immunostained	to	detect	NG2	(green)	and	Sox10	(red).	
Pediatric	images	demonstrate	hypertrophic	NG2-cells	(co-stained	with	
Sox10)	and	some	NG2	immunoreactivity	on	blood	vessels	at	24	hours	post-
MCAo	(B).	Increased	density	of	NG2-cells	at	3-	and	7-days	post-MCAo	in	
pediatric	mice	(C,	D).	Adult	images	demonstrate	loss	of	NG2-cells	at	24	hours	
(F)	and	3	days	(G)	post-MCAo	with	highly	levels	of	NG2	expression	localized	
to	blood	vessels.	NG-2	cells	repopulate	the	adult	lesion	at	7	days	post-MCAo	
while	blood	vessel	NG2	immunoreactivity	remains	prevalent	(H).	White	scale	
bars:	100	μm.	
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was	significantly	elevated	relative	to	contralateral	striatum	(Figure	4-4H,	K).	
Overall,	these	results	suggest	that	pediatric	OPCs	are	more	resistant	to	ischemic	
injury	than	adult	OPCs,	and	they	respond	earlier	to	the	injury	than	adult	OPCs.		
	
Figure	4-8.	Vascular	and	pericyte	responses	to	MCAo	in	pediatric	versus	
adult	mice.	Ischemic	and	control	pediatric	(A-D)	and	adult	(E-H)	sections	
were	immunostained	to	detect	CD13	(green)	and	Glut-1	(red).	Arrowheads	
indicate	extravascular	CD13	immunostaining.	Quantification	of	total	vessel	
length	and	total	number	of	vessel	segments	in	pediatric	(I	and	J,	respectively)	
and	adult	(L	and	M,	respectively)	striatum	from	ischemic	(Ipsi,	open	bars)	
and	control	(Contra,	dark	bars)	samples.	The	area	of	colocalized	CD13	and	
Glut-1	immunoreactivity	was	quantified	in	pediatric	(K)	and	adult	(N)	
samples.	White	scale	bars:	250	μm.	*p-value	<	0.05.	
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Mature	oligodendrocytes	are	resistant	to	ischemia	in	the	pediatric	brain.	To	
our	surprise,	as	with	the	OPCs,	mature	oligodendrocytes	(CC1/Sox10-double	
positive	cells)	in	the	pediatric	brain	were	not	significantly	affected	by	MCAo	at	any	
of	the	time	points	examined	relative	to	the	contralateral	hemisphere	(Figure	4-4A-D,	
J).	In	contrast,	in	the	adult	brain,	mature	oligodendrocytes	were	diminished	at	24	
hours	post-MCAo	in	the	ipsilateral	striatum	compared	to	the	contralateral	striatum	
(Figure	4-4F,	L)	and	the	number	of	mature	oligodendrocytes	remained	decreased	at	
3	days	post-MCAo	(Figure	4-4G,	L).	Unexpectedly,	between	3	and	7	days	post-MCAo,	
the	loss	of	mature	oligodendrocytes,	as	defined	by	CC1	expression,	was	reversed,	
and	by	7	days,	the	number	of	CC1-expressing	oligodendrocytes	was	significantly	
elevated	in	the	adult	ipsilateral	striatum	relative	to	the	contralateral	striatum	
(Figure	4-4B,	I).	To	confirm	the	remarkable	resistance	of	mature	oligodendrocytes	
following	pediatric	ischemic	stroke,	PLP-EGFP	transgenic	mice,	in	which	enhanced	
green	fluorescent	protein	(EGFP)	is	expressed	under	control	of	the	myelin	
proteolipid	protein	(PLP)	promoter	(Mallon	et	al.,	2002),	were	utilized	to	assess	
morphological	changes	following	ischemia.	At	24	hours	post-MCAo	in	pediatric	
mice,	PLP-EGFP-expressing	oligodendrocyte	cell	bodies	were	large	and	seemingly	
healthy	with	intact	myelin	processes	(Figure	4-4M).	In	adult	mice	at	24	hours	post-
MCAo,	the	PLP-EGFP-expressing	cells	were	shrunken	with	fragmented	and	
disorganized	myelin	processes	(Figure	4-4N).	
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Figure	4-9.	Decreased	oxidative	damage	and	increased	anti-oxidant	
capacity	after	pediatric	MCAo	compared	to	adult.		
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Myelin	damage,	axon	pathology,	and	long-term	tissue	loss	are	spared	in	pediatric,	but	
not	adult,	ischemia.	Ischemia	causes	ultrastructural	damage	to	both	
oligodendrocytes	and	myelin	in	adult	rodents	(Pantoni	et	al.,	1996;	Goldenberg-
Cohen	et	al.,	2005).	Therefore,	we	examined	the	myelinated	axon	bundles	that	
course	though	the	striatum	(pencil	fibers)	for	ischemia-induced	damage	in	adult	and	
pediatric	tissue.	Pediatric	myelin	remained	intact	compared	to	contralateral	tissue	
at	all	time	points	examined	(Figure	4-5A-D).	G-ratio	analysis	demonstrates	that	the	
thickness	of	myelin	was	unaffected	in	the	ipsilateral	fibers	compared	to	the	
contralateral	fibers	at	all	time	points	examined	(Figure	4-5I).	In	contrast,	adult	
tissue	showed	severe	ultrastructural	damage,	including	demyelination	and	axon	
Figure	4-9.	Decreased	oxidative	damage	and	increased	anti-oxidant	
capacity	after	pediatric	MCAo	compared	to	adult.	(A-H)	Ischemic	and	
control	pediatric	(A-D)	and	adult	(E-H)	sections	were	immunostained	to	
detect	GSTπ	(green)	and	Sox10	(red).	High	basal	expression	of	GSTπ	was	
observed	in	pediatric	striatal	oligodendrocytes	(A)	and	low	basal	expression	
in	adult	striatal	oligodendrocytes	(E).	GSTπ	expression	remains	high	in	
pediatric	striatal	oligodendrocytes	after	MCAo	(B-D)	and	is	upregulated	by	
remaining	adult	oligodendrocytes	after	MCAo	(F-H).		(I-L)	High	magnification	
images	of	PLP-EGFP	expressing	oligodendrocytes	24	hours	after	MCAo	
demonstrating	high	GSTπ	expression	in	EGFP	expressing	oligodendrocytes	in	
both	the	contralateral	(I)	and	ipsilateral	(J)	striatum	of	pediatric	mice.	Low	
GSTπ	expression	was	observed	in	contralateral	EGFP	expressing	
oligodendrocytes	in	adult	mice	(K)	and	was	upregulated	in	injured	EGFP	
expressing	oligodendrocytes	in	the	ipsilateral	striatum	(L).	Ischemic	PLP-
EGFP	expressing	pediatric	(M,	N)	and	adult	(O,	P)	sections	were	
immunostained	to	detect	nitrotyrosine	(3-NT,	red).	Moderate	3-NT	
expression	observed	in	pediatric	animals	at	24	hr	(M),	which	mostly	resolved	
3	d	after	MCAo	(N).	High	3-NT	expression	observed	in	adult	animals	at	24	hr	
post-MCAo	(N)	and	remained	high	after	3	d	(N).	Sections	were	also	
immunostained	to	detect	HO-1	(Q,	R,	green)	and	Sox10	(red).	High	HO-1	was	
observed	in	pediatric	sections	at	24	hr	post-MCAo	(Q),	and	often	colocalized	
with	Sox10	expressing	oligodendrocytes	(Q’,	arrowheads).	Adult	expression	
of	HO-1	after	MCAo	was	much	lower	(R)	and	primarily	localized	to	blood	
vessels	(R’).	White	scale	bars:	100	μm	(A-H,	M-R),	40	μm	(Q’).	Green	scale	
bars:	10	μm.	
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swelling,	as	early	as	24	hours	post-MCAo	and	continuing	through	7	days	post-MCAo	
(Figure	4-5E-H).	The	tissue	was	then	examined	for	histological	signs	of	axon	
pathology	within	the	myelinated	pencil	fibers.	SMI32	monoclonal	antibody	detects	
non-phosphorylated	neurofilament,	which	in	normal	tissue	is	found	in	cell	bodies,	
dendrites	and	thick	axons.	SMI32	also	accumulates	in	damaged	axons,	and	has	been	
used	as	a	measure	of	axonal	pathology	(Sherriff	et	al.,	1994).	High	magnification	
images	from	axonal	fibers	in	the	pediatric	samples	7	days	post-MCAo	showed	
scattered	signs	of	axon	pathology,	including	SMI32	immunoreactivity	and	axonal	
swellings	in	the	ipsilateral	striatum	(Figure	4-5J).	By	contrast,	adult	axonal	fibers	
displayed	numerous	axonal	swellings	and	increased	SMI32	staining	(Figure	4-5K).		
To	assess	the	long-term	consequences	of	MCAo	on	pediatric	and	adult	tissue,	
we	analyzed	animals	30	days	after	MCAo.	Tissue	was	immunostained	for	myelin	
oligodendrocyte	glycoprotein	(MOG)	and	low	magnification	images	allow	analysis	of	
global	changes	in	gross	anatomy	in	these	tissues.	Pediatric	tissue	showed	overall	
preservation	of	all	major	brain	regions,	including	striatal	and	cortical	tissue,	30	days	
after	MCAo	(Figure	4-5L).	Conversely,	adult	tissue	showed	major	loss	of	striatal	and	
cortical	tissue	in	the	ipsilateral	hemisphere,	resulting	in	cavitation,	severe	scar	
formation,	and	enlargement	of	the	lateral	ventricle	(Figure	4-5M).	This	tissue	loss	
precluded	detailed	comparison	of	long-term	consequences	of	MCAo	between	
samples	of	these	age	groups,	but	in	general,	immunohistochemical	analysis	of	
pediatric	tissue	indicated	little	damage	(data	not	shown).		
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Differential	injury	progression	in	pediatric	versus	adult	stroke.		Given	the	
dramatic	differences	in	tissue	damage	between	pediatric	and	adult	tissue	after	
ischemia,	we	next	investigated	other	cellular	responses	to	ischemia	that	might	differ	
between	pediatric	and	adult	stroke.	At	24	hours	post-MCAo,	there	was	diffuse	
astrogliosis	as	defined	by	GFAP	immunoreactivity,	in	both	pediatric	and	adult	
cortex,	corpus	callosum	and	striatum	(Figure	4-6A,	B,	E,	F).	By	3	days	post-MCAo,	
GFAP-positive	astrocytes	were	evident	in	the	cortex	and	corpus	callosum	
surrounding	the	lesion	core	in	both	pediatric	and	adult	tissue,	with	significant	
GFAP-immunoreactivity	in	the	medial	striatum	in	the	pediatric	samples	(Figure	4-
6C,	G).	In	pediatric	mice	starting	at	7-days	post-MCAo,	the	GFAP-immunoreactivity	
was	expressed	through	the	entire	ipsilateral	striatum,	including	the	lesion	core	
(Figure	4-6D),	whereas	the	astrocytic	response	remained	confined	to	the	peri-
infarct	region	in	adult	mice	(Figure	4-6H).		
Another	major	element	of	damage	following	ischemia	is	fibrinogen	
deposition,	which	leads	to	fibrotic	scar	formation.	In	pediatric	tissue,	very	little	
fibrinogen	immunoreactivity	was	noted	at	any	time	point	examined	(Figure	4-6A-D).	
In	adult	tissue,	however,	some	fibrinogen	deposition	was	observed	starting	as	early	
as	24	hours	post-MCAo	(Figure	4-6F).	At	3	days	post-MCAo,	heavy	fibrinogen	
deposition	was	observed	in	the	ischemic	core,	particularly	around	blood	vessels	
(Figure	4-6G,	arrowheads).	By	7	days,	a	broad	sheet	of	fibrinogen	deposition	was	
observed	throughout	the	ischemic	core	in	adult	tissue	(Figure	4-6H).	Thus,	
astrogliosis	was	more	widespread	in	the	pediatric	ischemic	core	while	fibrinogen	
deposition	was	limited.	The	combination	of	these	two	factors	may	have	protective	
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effects	maintaining	the	injured	tissue	and	preventing	long-term	tissue	loss	in	
pediatric	mice.	
	 We	assessed	the	effect	of	ischemia	on	NG2	proteoglycan	expressing	OPCs	
(NG2-cells).	In	pediatric	mice	at	24	hours	post-MCAo,	NG2-cells	became	
hypertrophic	with	increased	NG2	immunoreactivity	(Figure	4-7B).	Similarly,	in	
adult	tissue	at	24	hours	post-MCAo,	NG2-cells	were	also	hypertrophic;	however	
there	were	fewer	of	them	(Figure	4-7F).	In	addition	to	altered	NG2-cells,	there	were	
changes	in	NG2	expression	associated	with	the	vasculature,	where	it	is	known	to	be	
expressed	by	pericytes	(Ozerdem	et	al.,	2001).	Both	pediatric	and	adult	tissue	at	24	
hours	post-MCAo	had	increased	NG2	immunoreactivity	on	blood	vessels	in	the	
lesion	core	(Figure	4-7B,	F).		In	pediatric	samples	at	3	days	and	7	days	post-MCAo	in	
the	ipsilateral	striatum,	we	observed	less	vascular	NG2	immunoreactivity	and	
increased	numbers	of	NG2-cells	that	still	appeared	hypertrophic	(Figure	4-7C,	D).	In	
adult	tissue,	on	the	other	hand,	there	were	very	few	NG2	cells	in	the	lesion	core	at	3	
days	post-MCAo.	Instead,	NG2	immunoreactivity	was	primarily	localized	to	the	
vasculature	(Figure	4-7G).	At	7	days	post-MCAo	in	adult	tissue,	vascular	NG2	
immunoreactivity	was	present;	however	NG2-cells	were	now	present	in	the	injured	
tissue	(Figure	4-7H).		
	
Maintained	vascular	integrity	within	the	ischemic	core	in	pediatric	mice.	Given	
the	increased	NG2	immunoreactivity	on	blood	vessels	in	the	lesion	core	of	adult	
animals	after	stroke,	we	examined	these	samples	for	differences	in	vascular	
integrity.	Tissue	was	stained	for	Glut-1,	a	marker	of	vascular	endothelia,	and	CD13,	a	
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pericyte	marker	(Figure	4-8).	Vascular	content	was	quantified	either	as	total	vessel	
length	or	the	number	of	vessel	segments	in	the	tissue.	In	pediatric	tissue,	there	were	
no	differences	in	the	total	vessel	length	or	the	number	of	vascular	segments	in	the	
ischemic	core	compared	to	the	corresponding	contralateral	region,	at	any	time	point	
examined	(Figure	4-8A-D,	I,	J).	In	the	first	24	hours	post-MCAo	in	the	adult,	there	
was	little	change	in	total	vessel	length	and	vessel	count	in	the	ischemic	core	(Figure	
4-8E-H,	L,	M).	However,	after	3	days,	there	was	a	significant	decrease	in	both	total	
vessel	length	and	number	of	vessel	segments	compared	to	the	corresponding	
contralateral	region	(Figure	4-8G,	L,	M),	which	became	more	severe	at	7	days	post-
MCAo	(Figure	4-8H,	L,	M).	
	 In	order	to	quantify	the	effects	of	MCAo	on	vascular	pericytes,	we	measured	
the	area	of	colocalized	immunostaining	between	CD13,	a	pericyte	marker,	and	Glut-
1	at	low	magnification.	The	effects	of	MCAo	on	vascular	pericytes	mirrored	those	of	
the	blood	vessels.		In	pediatric	samples,	CD13	immunoreactivity	was	preserved	at	all	
time	points	examined	(Figure	4-8A-D,	K).	As	with	the	vasculature,	there	was	little	
change	in	CD13	immunoreactivity	at	24	hours	post-MCAo	in	adult	samples	(Figure	
4-8E-H,	M).	However,	after	3	days	and	7	days,	there	was	a	significant	decrease	in	
CD13	immunoreactivity	that	colocalized	with	Glut-1	(Figure	4-8E-H,	M).	
Interestingly,	starting	at	3	days	post-MCAo	and	continuing	at	7	days,	we	observed	
extravascular	CD13	expression	in	the	striatal	parenchyma	(Figure	4-8G,	H,	
arrowheads),	an	effect	not	observed	in	pediatric	samples	at	any	time.	
	 	 	
87	
Enhanced	protection	from	oxidative	damage	in	pediatric	oligodendrocytes.	
Because	pediatric	oligodendrocytes	exhibited	reduced	sensitivity	to	ischemia	
compared	to	adult	oligodendrocytes,	we	sought	to	identify	a	possible	mechanistic	
explanation	for	this	difference	in	ischemic	susceptibility.	Glutathione	S-transferase	
pi	(GSTπ)	is	an	enzyme	that	is	upregulated	in	response	to	oxidative	stress	and	plays	
a	key	role	in	reducing	the	byproducts	of	oxidative	stress	(Huang	et	al.,	2004;	Hayes	
et	al.,	2005).	In	the	CNS,	GSTπ	is	expressed	specifically	in	myelinating	
oligodendrocytes	(Tansey	and	Cammer,	1991;	Zhang	et	al.,	2014).	We	observed	high	
basal	levels	of	GSTπ	immunoreactivity	in	oligodendrocytes	(Sox10-positive	cells)	in	
the	uninjured	pediatric	striatum	(Figure	4-9A),	consistent	with	the	concept	that	
these	cells	are	in	a	state	of	active	myelination.	GSTπ	immunoreactivity	remained	
high	in	striatal	oligodendrocytes	after	pediatric	MCAo	throughout	the	reperfusion	
period	(Figure	4-9B-D).	By	contrast,	in	the	uninjured	adult	striatum,	very	few	
Sox10-positive	oligodendrocytes	expressed	GSTπ	(Figure	4-9E).	However,	in	
response	to	ischemia,	a	marked	upregulation	of	GSTπ	in	the	ipsilateral	striatum	was	
seen	at	all	time	points	examined	(Figure	4-9F-H).		
	 Morphologically,	the	GSTπ-positive	cells	in	the	ipsilateral	adult	striatum	
resemble	oligodendrocytes;	however	we	were	unable	to	identify	them	as	such	
because	Sox10	immunostaining	was	lost	after	MCAo	in	adult	mice	(Figure	4-9F,	G).	
In	order	to	confirm	that	GSTπ	was	upregulated	in	adult	oligodendrocytes	after	
MCAo,	we	immunostained	tissue	for	GSTπ	from	PLP-EGFP	expressing	mice	after	
MCAo,	in	which	EGFP	was	still	present	in	deteriorating	oligodendrocytes	in	the	adult	
striatum	(Figure	4-9N).	As	observed	in	wild	type	mice,	pediatric	PLP-EGFP	mice	
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expressed	high	levels	of	GSTπ	in	oligodendrocytes	in	both	the	contralateral	and	
ipsilateral	striatum	(Figure	4-9I,	J).	In	contrast,	PLP-EGFP-positive	oligodendrocytes	
in	the	adult	striatum	expressed	very	low	levels	of	GSTπ	(Figure	4-9K).	In	response	
to	MCAo,	remaining	EGFP-positive	oligodendrocytes	in	the	ipsilateral	striatum	
upregulated	GSTπ	expression,	but	were	shrunken	with	fragmented	myelin	
processes	(Figure	4-9L).			
We	next	examined	tissues	for	evidence	of	oxidative	damage	and	other	anti-
oxidant	responses.	Nitrosylated	tyrosine	is	a	marker	of	oxidative	stress	(Virág	et	al.,	
2003;	Warner	et	al.,	2004).	Immunostaining	for	nitrotyrosine	(3-NT)	showed	that	in	
pediatric	mice,	moderate	levels	of	3-NT	were	observed	at	24	hours	post-MCAo	
(Figure	4-9M),	with	only	trace	amounts	left	by	3	days	post-MCAo	(Figure	4-9N).	In	
contrast,	adult	tissue	showed	high	levels	of	3-NT	at	24	hours	post-MCAo,	which	
further	increased	at	3	days	post-MCAo	(Figure	4-9O,	P	respectively).	3-NT	
immunostaining	was	not	observed	in	oligodendrocytes	in	any	of	the	tissue	
examined,	as	co-localization	with	PLP-EGFP	was	not	observed	(Figure	4-9M-P).	
Heme	oxygenase	expression	is	induced	by	oxidative	stress	and	increased	expression	
of	this	enzyme	is	associated	with	protective	effects	from	oxidative	damage	(Wang	et	
al.,	2008).	Immunostaining	against	heme	oxygenase	1	(HO-1)	in	pediatric	and	adult	
tissue	showed	higher	levels	of	HO-1	in	pediatric	striatum	than	adult	(Figure	4-9Q,	R	
respectively).	Furthermore,	HO-1	co-localized	with	many	Sox10-positive	
oligodendrocytes	in	the	pediatric	striatum	(Figure	4-9Q’,	arrowheads),	whereas	it	
seemed	to	localize	primarily	to	blood	vessels	in	the	adult	striatum	(Figure	4-9R’).		
We	examined	other	anti-oxidant	enzymes,	including	glutamate-cysteine	ligase,	
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glutathione	reductase,	and	glutathione	peroxidase;	however,	we	were	unable	to	
detect	significant	expression	of	these	enzymes	(data	not	shown).	Together,	these	
data	suggest	that	compared	to	adults,	pediatric	mice	experience	less	oxidative	
damage	and	have	an	increased	anti-oxidant	capacity.	
	
Discussion	
	
	 Pediatric	stroke	has	received	very	little	research	attention	despite	major	
economic	and	quality	of	life	considerations.	This	is	in	part	due	to	a	lack	of	
experimental	models	with	which	to	study	pediatric	stroke.	Thus,	the	recent	
development	of	a	rodent	experimental	model	of	pediatric	ischemic	stroke	allows	
detailed	investigation	of	the	pathological	events	that	underlie	this	condition	(Herson	
et	al.,	2013),	and	most	importantly,	direct	comparison	with	adult	stroke	using	the	
same	model,	as	shown	in	this	study.	The	majority	of	stroke	research	focuses	on	gray	
matter	damage,	with	proportionally	less	attention	paid	to	white	matter	and	
myelinated	axons,	and	this	is	particularly	true	in	pediatric	stroke.	The	current	study	
describes	for	the	first	time	the	glial	and	white	matter	response	after	late	pediatric	
MCAo.	We	made	the	counter-intuitive	observation	that	pediatric	oligodendrocytes	
are	remarkably	resistant	to	ischemic	injury,	despite	their	high	metabolic	demand	
during	this	developmental	period	of	active	myelin	production.	Consistent	with	
resistance	of	oligodendrocytes	to	ischemia,	myelinated	axons	are	preserved	in	the	
pediatric	brain	compared	to	adult	brain.	Thus,	the	overall	progression	of	injury	in	
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the	pediatric	and	adult	brains	was	significantly	different,	due	to	differential	glial	cell	
responses	following	cerebral	ischemia.	
	 Not	surprisingly,	both	pediatric	and	adult	mice	exhibited	extensive,	and	
roughly	equivalent,	ischemic	injury	and	neuronal	cell	death	after	MCAo	(Figures	4-2,	
4-3).	However,	despite	widespread	neuron	loss,	relative	preservation	of	
oligodendrocytes	and	myelin	was	seen	in	pediatric	mice.	Oligodendrocytes	have	
been	shown	previously	to	be	highly	sensitive	to	ischemia	in	both	neonatal	and	adult	
tissue	(Dewar	et	al.,	2003;	Sozmen	et	al.,	2012;	Back	and	Rosenberg,	2014).	Other	
studies	have	reported	that	adult	oligodendrocytes	exhibit	signs	of	ultrastructural	
damage	as	early	as	30	minutes	after	ischemia	(Pantoni	et	al.,	1996).	While	we	
cannot	rule	out	the	possibility	that	pediatric	oligodendrocytes	in	our	model	could	
undergo	some	level	of	damage	immediately	after	ischemia	and	then	recover	by	24	
hours	post-MCAo,	adult	oligodendrocytes	eventually	died,	whereas	the	pediatric	
oligodendrocytes	in	this	study	did	not.		
While	the	mechanism	of	resistance	in	pediatric	oligodendrocytes	remains	
unclear,	we	made	the	surprising	observation	of	different	patterns	of	antioxidant	
expression	in	pediatric	and	adult	striatal	oligodendrocytes.	Oxidative	stress	is	a	
major	contributing	factor	to	the	pathophysiology	of	ischemic	stroke	(Allen	and	
Bayraktutan,	2009).	Oligodendrocytes	in	the	neonatal	and	adult	brains	have	been	
shown	to	be	damaged	by	oxidative	damage	following	hypoxia-ischmia	injury	
(Dewar	et	al.,	2003;	Back	and	Rosenberg,	2014;	Mifsud	et	al.,	2014),	however,	a	
direct	comparison	between	ages	using	the	same	experimental	model	had	not	been	
performed	prior	to	this	report.	We	observed	that	uninjured	pediatric	
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oligodendrocytes	in	the	striatum	expressed	high	levels	of	GSTπ	and	HO-1	and	
corresponding	adult	cells	expressed	low	amounts	of	these	enzymes.	In	the	ischemic	
core,	GSTπ	remained	elevated	in	pediatric	oligodendrocytes	and	was	upregulated	by	
injured	adult	oligodendrocytes.	Interestingly,	our	data	in	adult	animals	is	consistent	
with	observations	in	adult	human	patients,	where	upregulation	of	blood	GSTπ	
serves	as	a	reliable	time	indicator	of	stroke	onset	(Turck	et	al.,	2012).	While	little	is	
known	regarding	the	role	of	GSTπ	in	healthy	or	injured	oligodendrocytes,	extensive	
evidence	indicates	that	GSTπ	is	an	important	protective	factor	following	oxidative	
damage	in	other	cellular	contexts	(Huang	et	al.,	2004;	Hayes	et	al.,	2005).		Therefore,	
it	is	likely	that	enhanced	anti-oxidant	capacity	in	pediatric	oligodendrocytes	
contributes	to	their	relative	insensitivity	to	ischemic	injury.	
	 White	matter	damage	is	observed	after	neonatal	hypoxia/ischemia,	resulting	
in	degeneration	and	maturation	arrest	of	late	oligodendrocyte	progenitors,	reduced	
myelination,	neuro-axonal	degeneration,	and	long-term	cognitive	impairment	(Back	
et	al.,	2002a;	Segovia	et	al.,	2008;	Huang	et	al.,	2009).	Furthermore,	stroke	in	adult	
mice	causes	myelin	loss,	neurodegeneration,	sensory/motor	deficits,	and	memory	
impairment	(Kalesnykas	et	al.,	2008;	Zhou	et	al.,	2013;	Blasi	et	al.,	2014).	Similar	to	
the	preservation	of	oligodendrocytes,	pediatric	myelin	was	also	preserved	in	the	
striatum	after	MCAo	with	only	minimal	axon	damage.	Adult	myelin	was	severely	
impacted	after	MCAo	and	signs	of	severe	axon	pathology	were	also	present.	This	is	
significant	because	in	adult	mice,	there	is	both	primary	neuron	loss	as	a	result	of	
ischemic	damage	as	well	as	secondary	neuron	loss	as	a	result	of	axon	degeneration.	
Since	pediatric	myelinated	axons	are	maintained	after	MCAo,	secondary	injury	is	
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presumably	also	decreased,	which	could	be	a	significant	contributor	to	the	
enhanced	long-term	recovery	after	stroke	in	pediatric	mice	compared	to	adults.		
In	investigating	other	glial	responses	to	MCAo,	we	observed	diffuse	
astrogliosis	throughout	the	lesioned	striatum	in	pediatric	mice	without	evidence	of	
fibrotic	scar	formation.	In	contrast,	adult	tissue	displayed	a	well-characterized	
demarcation	of	the	ischemic	core	by	reactive	astrocytes,	as	observed	previously	
(Fernández-Klett	et	al.,	2013),	which	eventually	became	engulfed	by	fibrinogen	
deposition,	resulting	in	permanent	tissue	loss.	The	tissue	that	was	lost	in	adult	mice	
was	maintained	in	pediatric	mice.	Similarly,	we	observed	a	gradual	decrease	in	both	
vascular	integrity	and	associated	pericyte	population	after	MCAo,	consistent	with	
previous	studies	demonstrating	vascular	density	correlating	to	stroke	outcome	in	
patients	(Krupinski	et	al.,	1994)	and	a	role	for	pericytes	in	tissue	pathology	after	
ischemia	(Sbarbati	et	al.,	1996;	Fernández-Klett	et	al.,	2013;	Hall	et	al.,	2014).	
Interestingly,	both	the	blood	vessel	network	and	their	associated	pericytes	
remained	intact	in	pediatric	mice	after	MCAo.	However,	the	mechanisms	
responsible	for	vasculature	destruction	in	adult	mice,	but	maintenance	in	pediatric	
mice,	are	not	clear.	Fibrinogen	deposition	around	blood	vessels	occurred	in	adult	
mice	at	3	days	post-MCAo,	at	the	same	time	that	the	vasculature	was	lost.	However,	
whether	fibrinogen	was	deposited	around	these	vessels	because	they	were	dying,	or	
the	deposition	caused	the	vessels	to	die,	is	currently	unknown.	Stromal	pericytes	
have	been	described	to	contribute	to	fibrotic	scar	formation	after	stroke	
(Fernández-Klett	et	al.,	2013),	and	could	be	the	source	of	fibrotic	scar	formation	
observed	in	our	tissue	(Figure	4-6G,	H).	The	current	studies	demonstrate	that	
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oligodendrocyte	and	OPC	survival	in	pediatric	tissue	correlates	with	blood	vessel	
integrity	after	MCAo,	endothelial	cells,	and	pericytes.	These	vascular	changes	could	
contribute	to	the	long-term	maintenance	of	tissue	observed	in	pediatric	tissue	
compared	to	adult	tissue.	The	current	studies	suggest	complex	interactions	within	
the	“oligovascular	niche”,	in	which	there	is	bidirectional	cross	talk	between	the	
cerebral	endothelium	and	oligodendrocytes/OPCs	(Arai	and	Lo,	2009;	Pham	et	al.,	
2012;	Yuen	et	al.,	2014).	Further	studies	are	warranted	to	assess	whether	the	
relative	preservation	of	oligodendrocytes	and	OPCs	influences	the	preservation	of	
vessel	integrity,	or	vice	versa.	Thus,	our	data	indicate	that	while	estimated	infarct	
volume	analyzed	using	standard	methods	of	acute	histological	injury	reveals	
comparable	acute	injury	in	the	adult	and	pediatric	brain,	progression	of	injury	
during	the	subacute	and	chronic	stages	are	different.	This	observation	has	profound	
implications	regarding	long-term	functional	deficits	and	potential	for	histological	
and	functional	plasticity	in	the	pediatric	brain	after	injury.	
	 Interestingly,	we	also	observed	sparing	of	pediatric	oligodendrocyte	
precursor	cells	(OPCs)	after	MCAo.	OPCs	are	the	most	proliferative	cell	in	the	brain	
and	are	evenly	distributed	throughout	brain	parenchyma	(Nishiyama	et	al.,	2002).	
OPCs	have	traditionally	been	viewed	with	regard	to	their	ability	to	respond	to	
demyelination	and	differentiate	into	new	myelin	forming	oligodendrocytes,	but	it	is	
becoming	increasingly	obvious	that	they	have	much	more	diverse	functions	both	in	
healthy	and	injured	brain	tissue	(Xu	et	al.,	2011;	Hughes	et	al.,	2013;	Yang	et	al.,	
2013).	In	this	light,	OPCs	are	more	accurately	labeled	as	NG2-cells	(or	NG2-glia)	
based	on	their	expression	of	the	NG2	proteoglycan	and	their	distinct	functionality	
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(Zuo	and	Nishiyama,	2013).	In	order	to	understand	if	this	population	of	cells	might	
mediate	some	of	the	differences	noted	following	pediatric	MCAo	relative	to	adult	
MCAo,	we	examined	the	NG2-cell	response	in	these	samples.		We	observed	a	
different	profile	of	NG2-cell	response	in	the	pediatric	and	adult	mice,	with	pediatric	
brain	having	large	numbers	of	NG2-cells	within	the	ipsilateral	striatum	during	the	
acute	phase	(3	days),	while	the	adults	did	not.	This	could	be	indicative	of	a	
protective	role	for	NG2-cells	in	the	post-ischemic	brain.	Indeed,	deficiency	of	NG2-
cells	in	adults	results	in	greater	infarct	volume	after	MCAo	(Wang	et	al.,	2011),	
highlighting	a	potential	protective	role	of	NG2-cells	after	ischemic	injury.	
Interestingly,	a	role	in	the	repair	process	is	also	indicated	for	NG2-cells	via	the	
generation	of	new,	myelin-forming	mature	oligodendrocytes	(Honsa	et	al.,	2012).	
Consistent	with	this	possible	restorative	role,	we	observed	recovery	of	NG2-cells	in	
the	adult	brain	at	delayed	time	points	(>7	days).	
In	conclusion,	we	have	described	very	different	pathological	sequelae	after	
MCAo	in	pediatric	and	adult	mice.	Despite	similar	amounts	of	striatal	cell	death	and	
neuronal	loss	between	the	two	age	groups,	we	observed	very	different	glial	
responses.	Whereas	oligodendrocytes	and	OPCs	were	lost	early	after	MCAo	in	adult	
mice,	these	cells	were	spared	in	pediatric	mice,	perhaps	due	to	enhanced	
antioxidant	defenses.	We	suggest	a	model	in	which	the	“oligovascular	niche”	is	
maintained	in	the	pediatric	brain,	culminating	in	unique	cellular	events	(diffuse	
gliosis,	reduced	fibrosis)	that	maintain	the	brain	parenchyma	to	a	greater	extent	
than	that	observed	in	adult	tissue.	These	results	suggest	that	specific	glial	responses	
are	important	mediators	of	long-term	tissue	preservation	after	ischemic	injury	in	
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pediatric	mice	and	represent	important	therapeutic	targets	in	order	to	improve	
stroke	treatment	and	recovery	in	all	age	groups.	
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CHAPTER	V	
DISCUSSION	
	
	 The	primary	objective	of	this	project	was	to	gain	a	better	understanding	of	
the	biology	of	the	actively	myelination	oligodendrocyte	in	the	developing	and	
injured	brain.	Specifically,	I	sought	to	identify	and	characterize	putative	negative	
regulators	of	myelination	and	examine	the	responses	of	the	developing	brain	to	
ischemic	injury.	I	identified	Shp2	as	a	potential	negative	regulator	of	CNS	
myelination	using	a	candidate	based	approach	and	expression	profiling	of	mRNA	
and	protein	during	development	in	wild	type	and	hypermyelinating	mutants	
(Chapter	II)	(Ahrendsen	and	Macklin,	2013).	I	then	went	on	to	characterize	the	
functional	role	of	oligodendrocyte	Shp2	and	showed	that	is	served	as	a	transient	
brake	during	early	myelin	formation	and	regulated	timely	remyelination	(Chapter	
III).	Finally,	I	demonstrated	that	actively	myelinating	oligodendrocytes	in	the	late	
pediatric	brain	are	resistant	to	ischemia-induced	damage,	potentially	by	having	a	
more	robust	anti-oxidant	capability	(Chapter	IV).		
	 The	actively	myelinating	oligodendrocyte	is	a	complex	cell	with	multiple	
functional	redundancies	built	in	to	ensure	proper	myelin	formation.	Indeed,	
significant	over	production	of	myelin	in	the	CNS	has	not	been	described	in	human	
subjects.	Therefore,	studying	the	signaling	mechanisms	regulating	this	process	in	
inherently	difficult.	However,	the	use	of	creative	transgenic	mouse	models	to	
specifically	manipulate	certain	signaling	pathways	specifically	within	
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oligodendrocytes	has	significantly	improved	our	understanding	of	the	molecular	
signals	driving	myelination.		
	 I	took	advantage	of	one	of	these	transgenic	animals,	the	hypermyelinating	
Akt-DD	mouse	(Flores	et	al.,	2008),	in	order	to	identify	putative	negative	regulators	
of	CNS	myelination.	To	this	end,	I	identified	Shp2.	I	was	then	able	to	demonstrate	a	
role	for	this	phosphatase	as	a	transient	brake	of	early	myelination.	However,	the	
signaling	mechanisms	affecting	myelin	overproduction	in	this	model	were	
unexpected,	as	neither	Akt/mTOR	nor	ERK	signaling	were	significantly	altered	by	
the	conditional	knockout	of	Shp2.	Instead,	FAK	signaling	was	the	predominant	
signaling	pathway	altered.	However,	I	cannot	rule	out	that	Akt/mTOR	and/or	ERK	
signaling	were	not	altered	in	individual	myelinating	cells,	as	the	sensitivity	of	
western	blots	may	not	be	able	to	detect	those	differences.	I	suggest	a	model	in	which	
Shp2	signaling	through	FAK	regulates	myelin	thickness	during	early	stages	of	
myelination	(Figure	5-1).	In	order	to	confirm	this	model,	a	Shp2/FAK	double	
knockout	transgenic	animal	would	need	to	be	produced.	If	the	model	is	correct,	the	
phenotypes	observed	in	the	Shp2	single	knockout	animal	would	be	mitigated	in	the	
Shp2/FAK	double	knockout.	I	also	suggest	that	Shp2/FAK	signaling	acts	in	parallel	
to	PI3K/Akt/mTOR	to	promote	myelination,	as	the	latter	pathway	was	unaffected	
by	Shp2	knockout	(Figure	5-1).	This	could	be	tested	directly	by	treating	Shp2	cKO	
animals	with	rapamycin,	which	would	block	mTOR	signaling.	If	the	two	pathways	
act	in	parallel,	blocking	mTOR	signaling	with	rapamycin	would	not	affect	
myelination	in	the	Shp2	cKO	mouse	because	FAK	signaling	would	still	be	
upregulated.	
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Figure	5-1.	Model	of	Shp2	regulation	of	CNS	myelination.	Extracellular	
ligand	(dark	blue)	binding	a	transmembrane	receptor	and	activating	the	
PI3K/Akt	pathway	(light	blue	icons).	Lipid	second	messengers	PIP2	and	PIP3	
indicated	in	yellow.	Negative	regulators	indicated	in	red.	Blunted	arrows	
indicate	inhibition.	Dashed	line	indicates	indirect	regulation.	Proposed	
activation	of	FAK	by	Shp2	to	promote	myelination	while	simultaneously	
inhibiting	Fyn	kinase	to	decrease	the	number	of	nascent	myelin	sheaths	per	
oligodendrocyte.	
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Shp2	has	also	been	shown	to	promote	the	localized	activation	of	Fyn	kinase	
(Yang	et	al.,	2010b).	It	has	also	been	observed	that	activation	or	reduction	of	Fyn	
kinase	in	oligodendrocytes	increases	or	decreases,	respectively,	the	number	of	
nascent	myelin	sheaths	produced	per	oligodendrocyte	(Czopka	et	al.,	2013).	In	our	
system,	we	observe	a	recovery	in	the	number	of	mature	oligodendrocytes	in	the	P28	
Shp2	cKO	brain.	However,	we	also	observe	decreased	numbers	of	myelinated	axons	
at	the	same	time.	Therefore,	I	propose	a	model	in	which	Shp2	influences	the	number	
of	myelinated	processes	extended	by	individual	oligodendrocytes	by	
downregulating	Fyn	kinase	(Figure	5-1).	It	would	be	interesting	to	test	whether	
activated	Fyn	kinase	is	reduced	in	Shp2	cKO	animals.	Indeed,	Fyn-null	mice	display	
significant	hypomyelination	and	reduced	number	of	myelinated	axons	in	multiple	
brain	regions	(Sperber	et	al.,	2001).	One	of	the	most	interesting	results	in	this	study	
is	the	observation	that	equal	numbers	of	oligodendrocytes	ensheath	fewer	axons,	
but	those	axons	that	do	become	ensheathed	have	thicker	myelin.	Serial	electron	
microscopy	reconstructions	and/or	mosaic	expression	of	EGFP	in	scattered	
oligodendrocytes	could	be	used	to	count	the	number	of	myelin	processes	from	
individual	oligodendrocytes.		
Interestingly,	when	Shp2	was	deleted	from	oligodendrocytes	during	later	
developmental	time	points,	myelination	was	unaffected.	Therefore,	more	sustained	
braking	mechanisms	seem	to	be	involved	in	the	long-term	regulation	of	CNS	myelin	
formation.	It	would	be	worth	examining	the	ultrastructure	of	Shp2	icKO	mice	via	
electron	microscopy	in	order	to	test	whether	individual	myelinated	axons	are	
altered.	In	the	case	of	the	Shp2	cKO	animals,	differences	in	myelination	could	only	
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be	observed	at	the	ultrastructural	levels.	The	current	data	cannot	rule	out	
definitively	that	Shp2	is	not	involved	in	the	long-term	maintenance	of	individual	
myelinated	axons.	However,	our	data	do	suggest	that	Shp2	is	an	early	negative	
regulator	of	myelination.	Tamoxifen	should	be	administered	to	Shp2	icKO	animals	
earlier	in	development,	such	as	from	P14-21,	in	order	to	test	this	hypothesis	
directly.	The	advantage	of	this	system	is	that	it	still	bypasses	the	early	generation	
and	differentiation	effects	that	Shp2	has	during	late	embryonic	and	early	postnatal	
development.	
The	finding	that	Shp2	may	act	as	a	transient	brake	of	early	CNS	myelination	
is	reminiscent	of	the	same	role	that	Dlg1	serves	in	peripheral	myelination	(Cotter	et	
al.,	2010).	In	the	PNS,	identification	of	Dlg1	as	a	transient	brake	of	myelination	led	to	
the	discovery	that	DDIT4	acts	as	a	sustained	negative	regulator	(Noseda	et	al.,	
2013).	The	studies	presented	here	could	similarly	provide	further	insight	into	other	
yet	unknown	molecular	regulators	of	myelination.	DDIT4	was	identified	by	RNA-seq	
analysis	of	Dlg1	conditional	knockout	animals	(Noseda	et	al.,	2013).	Similar	mRNA	
sequencing	analyses	should	be	done	using	Shp2	cKO	tissue	to	identify	other	more	
sustained	regulators	of	CNS	myelination.			
	 These	results	highlight	three	significant	factors	involved	in	the	coordination	
of	myelin	production.	The	first	is	that	a	single	molecule	can	serve	multiple	roles	in	
an	oligodendrocyte	depending	on	its	maturation	stage.	Shp2	has	now	been	shown	to	
influence	oligodendrocyte	generation,	proliferation,	differentiation,	and	early	
myelination	(Zhu	et	al.,	2010;	Ehrman	et	al.,	2014);	and	Chapter	III	here).	
Furthermore,	a	given	protein	can	influence	progression	into	different	stages	of	
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maturation.	It	is	possible	that	Shp2	conditional	knockout	early	in	oligodendrocyte	
differentiation	influenced	the	molecular	milieu	during	early	myelination.	Therefore,	
inducible	knockout	systems	are	necessary	to	show	that	a	given	molecule	is	
responsible	during	a	given	stage	or	transition	between	stages	of	oligodendrocyte	
maturation.	However,	the	lack	of	synchrony	amongst	oligodendrocyte	populations	
confounds	this	issue	even	further.	
Second,	it	is	unlikely	that	a	single	signaling	pathway	is	responsible	for	the	
coordinated	production	of	myelin.	While	certain	pathways,	such	as	Akt/mTOR	and	
ERK	are	clearly	involved	in	driving	myelination	(Flores	et	al.,	2008;	Ishii	et	al.,	
2013),	the	relative	contribution	of	each	of	these	individual	pathways,	and	how	they	
interact	and	compensate	for	each	other	and	other	pathways	remains	unknown.	
Indeed,	the	Akt/mTOR	and	ERK	pathways	have	significant	crosstalk	in	cultures	
oligodendrocytes,	where	inhibition	of	one	affects	the	other	(Dai	et	al.,	2014).	
Therefore,	while	conditional	knockout	studies	provide	valuable	insight	into	the	
function	of	a	single	gene,	in	order	to	gain	a	more	thorough	insight	into	the	molecular	
mechanisms	governing	myelination	it	will	be	necessary	to	create	strategic	double	
and	triple	transgenic	animals.	For	example,	is	Akt	overexpression	sufficient	to	
rescue	hypomyelination	observed	in	ERK1/2	knockout	animals?	This	was	done	
successfully	to	show	that	overexpression	of	Akt	in	oligodendrocytes	could	rescue	
myelin	deficits	in	BACE1	knockout	animals	(Hu	et	al.,	2013)	and	also	to	determine	
the	molecular	mechanisms	of	node	assembly	formation	in	the	CNS	(Susuki	et	al.,	
2013).	
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	 Third,	large-scale	genomic	experiments	need	to	be	conducted	to	better	
characterize	the	molecular	features	of	individual	transgenic	and	wild	type	animals	
during	different	stages	of	development.	Using	single	cell	RNA-seq,	as	many	as	six	
individual	subclasses	of	oligodendrocytes	were	identified	(Zeisel	et	al.,	2015).	
Similar	studies	during	multiple	developmental	time	points	will	provide	valuable	
information	on	how	these	subclasses	are	regulated	during	different	stages	of	brain	
development.	Furthermore,	direct	comparisons	between	different	transgenic	
models	will	enable	the	identification	of	specific	pathways	and	proteins	responsible	
for	myelin	formation	and	how	they	might	interact.	This	would	also	help	bridge	the	
gap	between	intracellular	signaling	and	transcriptional	regulation	of	myelination,	a	
major	question	that	still	exists	in	the	field.	
	 While	much	work	still	remains	to	better	understand	myelin	formation	during	
normal	development,	even	greater	work	remains	to	understand	myelin	repair	after	
injury.	Many	aspects	of	developmental	myelination	are	recapitulated	during	
remyelination	and	provide	valuable	information	regarding	the	remyelination	
process	(Fancy	et	al.,	2011a).	I	show	here	that	the	function	of	Shp2	in	regulating	
timely	oligodendrocyte	differentiation	during	development	is	conserved	during	
remyelination.	The	identification	of	factors	that	influence	oligodendrocyte	
differentiation	during	remyelination	has	significant	therapeutic	implications,	as	
impaired	oligodendrocyte	differentiation	following	multiple	episodes	of	
demyelination	is	thought	to	contribute	to	the	pathology	of	multiple	sclerosis	(Chang	
et	al.,	2002).	However,	there	are	currently	no	FDA	approved	medications	for	
promoting	remyelination.	
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	 Experimental	models	of	de/remyelination	have	suggested	that	a	variety	of	
molecules	are	involved	in	regulating	oligodendrocyte	differentiation	and	myelin	
repair	after	injury.	Notable	examples	of	factors	that	promote	oligodendrocyte	
differentiation	and	enhance	remyelination	include	Olig2	(Wegener	et	al.,	2015),	
Wnt/β-catenin/Axin2	(Fancy	et	al.,	2011b),	and	death	receptor	6	(Mi	et	al.,	2011).	
Interestingly,	fibroblast	growth	factor	signaling	did	not	influence	the	recovery	of	
acute	demyelinated	lesions,	but	enhanced	recovery	of	chronic	lesions	(Furusho	et	
al.,	2015).	While	many	therapeutic	targets	are	emerging	as	a	result	of	these	types	of	
studies,	our	understanding	of	the	process	as	a	whole	and	how	these	individual	
molecules	interact	and	cooperate	throughout	the	process	remains	a	significant	
limiting	factor	in	generating	useful	therapeutics	for	use	in	human	diseases.		
Large-scale	genomic	studies	on	oligodendrocytes	during	remyelination	are	
lacking	and	would	provide	valuable	insight	into	the	process	as	a	whole.	Are	
individual	factors,	such	as	Shp2	and	others	outlined	above,	actually	involved	in	the	
normal	(wild-type)	remyelination	process	or	are	they	specific	to	the	transgenic	
animal	being	investigated?	Furthermore,	remyelination	in	the	mouse	brain	is	
incredibly	robust	(Matsushima	and	Morell,	2001;	Sachs	et	al.,	2014)	and	it	is	
unknown	how	the	process	compares	to	that	in	humans.	Post-mortem	samples	from	
MS	brains	have	been	used	to	pinpoint	specific	molecular	differences	that	could	be	
involved	in	various	stages	of	MS	pathology	(Dutta	et	al.,	2011;	2013).	Similar	studies	
could	be	performed	on	isolated	cells	in	demyelinated	lesions	to	determine	
oligodendrocyte	intrinsic	factors	responsible	for	differentiation	failure.		
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Remyelination	efficiency	and	oligodendrocyte	responses	to	neurological	
injury	are	generally	studied	in	adult	test	subjects	because	these	types	of	diseases	are	
generally	associated	with	adulthood.	However,	it	is	becoming	increasingly	evident	
that	any	of	these	conditions	occur	during	all	stages	of	life,	including	childhood.	
Furthermore,	children	generally	recover	better	after	brain	insult	(depending	
primarily	on	age	at	insult	and	time	since	insult)	but	the	mechanisms	responsible	for	
enhanced	recovery	remain	speculative	(Anderson	et	al.,	2011).	In	particular,	the	
responses	of	actively	myelinating	oligodendrocytes	in	the	late	pediatric	brain	to	
acute	brain	injury	had	not	been	examined	prior	to	this	report.		
I	showed	that	compared	to	adult	animals,	oligodendrocytes	in	the	late	
pediatric	brain	survive	an	acute	episode	of	experimentally	induced	cerebral	
ischemia	to	a	far	greater	degree.	Although	the	exact	mechanism	of	this	resistance	by	
pediatric	oligodendrocytes	remains	to	be	determined,	I	observed	interesting	
differences	in	the	anti-oxidant	responses	in	pediatric	versus	adult	oligodendrocytes	
following	ischemia.	Oligodendrocytes	are	traditionally	considered	quite	sensitive	to	
oxidative	stress	in	the	neonatal	brain	as	well	as	in	the	adult	brain	(Dewar	et	al.,	
2003;	Back	and	Rosenberg,	2014);	however,	in	the	neonatal	brain	it	is	the	late-stage	
oligodendrocyte	precursor	cell	that	is	susceptible	to	oxidative	stress,	while	in	the	
adult	it	is	the	terminally	differentiated	post-myelinating	cell.	The	actively	
myelinating	oligodendrocyte,	which	are	enriched	in	the	late	pediatric	brain,	had	not	
been	examined	in	the	context	of	ischemia	until	this	report	and	I	propose	that	this	
subclass	of	oligodendrocyte	has	enhanced	anti-oxidant	capacity	than	other	
subclasses.	One	way	in	which	this	hypothesis	can	be	tested	is	to	conditionally	delete	
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important	genes	involved	in	the	anti-oxidant	response	from	oligodendrocytes.	I	
would	expect	that	pediatric	oligodendrocytes	would	be	rendered	more	susceptible	
to	ischemia-induced	injury	in	the	absence	of	vital	anti-oxidant	enzymes,	such	as	
Nrf2,	GSTπ,	and	heme	oxygenase-1.	
GSTπ	is	just	one	example	of	a	candidate	anti-oxidant	gene	whose	function	
could	be	tested	both	in	the	developmental	context	as	well	as	following	ischemic	
injury.	GSTπ	is	a	useful	histological	marker	of	mature	oligodendrocytes	(Tansey	and	
Cammer,	1991)	but	very	little	is	known	about	the	functional	role	of	GSTπ	in	healthy	
or	injured	oligodendrocytes,	although	glutathione	depletion	increases	the	
susceptibility	of	cultured	oligodendrocytes	to	oxidative	stress	(Back	et	al.,	1998).	
GSTπ	is	an	important	mediator	of	oxidative	damage	in	other	cellular	contexts	
(Huang	et	al.,	2004;	Hayes	et	al.,	2005)	and	has	been	used	as	a	time	indicator	of	
stroke	onset	in	humans	(Turck	et	al.,	2012).	It	is	reasonable	to	suggest	that	GSTπ	
could	serve	important	anti-oxidant	functions	both	during	active	myelination,	a	
process	with	extraordinary	metabolic	demands	(Harris	and	Attwell,	2012)	in	the	
pediatric	brain,	as	well	as	after	ischemic	injury,	a	process	known	to	induce	
significant	oxidative	damage	(Allen	and	Bayraktutan,	2009).	The	data	presented	in	
Chapter	IV	demonstrated	that	GSTπ	levels	are	higher	in	pediatric	compared	to	adult	
striatal	oligodendrocytes,	and	also	coincides	with	the	peak	of	active	myelination.	If	
GSTπ	is	necessary	to	mitigate	oxidative	stress	in	response	to	the	high	metabolic	
demands	of	the	actively	myelinating	oligodendrocyte	in	the	pediatric	brain,	it	would	
be	reasonable	to	suggest	that	mice	lacking	GSTπ	would	display	myelin	
abnormalities	indicative	of	increased	oxidative	stress,	such	as	myelin	decompaction	
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and	tight	junction	disruption.	These	myelin	abnormalities	were	observed	in	mice	
expressing	increased	levels	of	nitric	oxide,	an	inducer	of	oxidative	stress	(Mayes	et	
al.,	2013).	
Oxidative	damage	is	one	pathological	component	of	ischemia,	particularly	
during	the	reperfusion	injury	that	occurs	following	restoration	of	blood	flow.	
Cellular	hypoxia	is	another	pathological	consequence	resulting	from	disrupted	
oxygen	transport.	White	matter	brain	regions	receive	proportionally	less	blood	flow	
than	gray	matter	regions	(Fisher,	2011).	However,	oligodendrocytes	can	develop	
normally	without	functioning	mitochondrial	electron	transport	by	utilizing	
glycolysis	instead	of	oxidative	phosphorylation	(Fünfschilling	et	al.,	2012).	Thus,	
proper	vascular	supply	to	white	matter	brain	regions	is	necessary	for	proper	
oligodendrocyte	function	but	not	necessarily	for	oxygen	dependent	energy	
metabolism.	This	concept	has	important	implications	in	how	we	think	about	white	
matter	ischemia,	as	oxygen	depletion	may	be	less	damaging	to	oligodendrocytes	
than	oxidative	damage	caused	by	reperfusion	injury.	The	cellular	sources	of	
oligodendrocyte	energy	substrates	are	only	beginning	to	be	understood	(Morland	et	
al.,	2007;	Nave,	2010).	How	these	energy	stores	are	mobilized	during	an	energy	
crisis,	such	as	ischemia,	have	yet	to	be	determined.	I	propose	that	pediatric	
oligodendrocytes	can	better	utilize	glycolytic	mechanisms	of	energy	metabolism,	
which	better	enables	them	to	withstand	energy	deprivation	during	ischemia.	This	
could	be	tested	by	genetically	disrupting	glycolysis	specifically	in	oligodendrocytes.	
The	concept	of	an	“oligovascular	niche”	has	recently	been	described	and	
addresses	the	direct	influence	that	oligodendrocytes	and	blood	vessel	endothelia	
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have	on	one	another	(Miyamoto	et	al.,	2014).	Oligodendrocyte	secreted	factors	can	
influence	vascular	remodeling	after	ischemia	(Pham	et	al.,	2012)	and	nitric	oxide	
produced	by	oligodendrocytes	affects	blood	brain	barrier	permeability	(Mayes	et	al.,	
2013).	On	the	other	hand,	endothelial	derived	trophic	factors	influence	OPC	
proliferation,	migration	and	proliferation	(Miyamoto	et	al.,	2014)	and	
oligodendrocyte	maturation	is	coupled	to	white	matter	angiogenesis	and	increased	
oxygen	supply	(Yuen	et	al.,	2014).	In	Chapter	IV	of	this	thesis,	I	showed	a	strong	
correlation	between	oligodendrocyte	health	and	vascular	health	following	ischemic	
injury,	which	seemed	to	have	major	long-term	effects	on	tissue	preservation.	Thus,	
exploring	the	mechanisms	underlying	communication	between	oligodendrocytes	
and	vascular	endothelia,	and	how	these	cells	respond	to	each	other,	could	have	
significant	impacts	in	preserving	tissue	function	and	promoting	recovery	after	
stroke.	
Together,	this	study	highlights	the	importance	of	the	actively	myelinating	
oligodendrocyte	as	a	unique	cell	type	in	the	developing	brain.	Understanding	the	
molecular	characteristics	governing	the	activity	and	responses	of	this	cell	complex	
cell	will	enable	more	focused	research	on	potential	therapies	aimed	at	modulating	
cellular	activities	of	oligodendrocytes.	Furthermore,	understanding	the	unique	
properties	of	actively	myelinating	oligodendrocytes	that	prevent	its	damage	during	
injury	might	enable	extrapolation	to	other	age	groups,	which	do	not	possess	the	
capabilities.		
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